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ABSTRACT  
The human P2Y2 receptor (hP2Y2R) is a G protein-coupled receptor that shows promise as a 
therapeutic target for many important conditions including anti-metastatic cancer therapy and more 
recently for the treatment of idiopathic pulmonary fibrosis. As such, there is a need for new 
hP2Y2R antagonists and molecular probes to study this receptor. Herein, we report the 
development of a new series of non-nucleotide hP2Y2R antagonists leading to the discovery of a 
series of fluorescent ligands containing different linkers and fluorophores based on the known, 
non-nucleotide hP2Y2R antagonist AR-C118925 (1). One of these conjugates 98 displayed 
micromolar affinity for the hP2Y2R (pKd = 6.32 ± 0.10; n=17) using a bioluminescence energy 
transfer (BRET) assay. Confocal microscopy with this ligand revealed displaceable membrane 
labeling of astrocytoma cells expressing un-tagged hP2Y2R. These properties, make 98 one of the 
first tools for studying hP2Y2R distribution and organization. 
INTRODUCTION 
P2Y receptors (P2YRs) are G protein-coupled receptors (GPCRs) that are activated by 
extracellular nucleotides. The P2Y family is composed of eight members encoded by distinct genes 
that can be subdivided into two groups based on their primary signaling through specific G 
proteins1 and sequence homology. The first sub-group includes the P2Y1,2,4,6,11 receptors which 
primarily signal though Gq,  with the second sub-group signaling through Gi encompassing the 
P2Y12,13,14 receptor subtypes.
2 Notably, the P2Y2 receptor (P2Y2R)  is activated by the endogenous 
agonists uridine-5′-triphosphate (UTP hP2Y2, EC50 = 140 nM) and adenosine-5′-triphosphate 
(ATP, hP2Y2, EC50 = 230 nM).
3 As the P2Y2R is predominately Gq-coupled,  receptor activation 
leads to stimulation  of phospholipase C, IP3 release and elevation of intracellular Ca
2+ 
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concentration, as well as the initiation of protein kinase C and activation of the mitogen activated 
protein kinase cascade.  
Defining the clinical role for P2Y2R antagonism has been hampered by the lack of high affinity 
and drug-like receptor antagonists.4  However, it has been reported that ATP released from tumor 
cell-activated platelets induces the opening of the endothelial barrier, leading to migration of tumor 
cells and hence cancer proliferation. More importantly, the P2Y2R was identified as the primary 
mediator of this effect; a strong reduction of tumor cell metastasis was observed in P2Y2R deficient 
mice revealing a therapeutic potential of P2Y2R antagonists as anti-metastatic agents.
5, 6 Recently, 
it has been reported that both inflammation and fibrosis were reduced in P2Y2R-deficient mice 
compared to wild type animals. In addition mechanistic studies have demonstrated that recruitment 
of neutrophils into the lungs, proliferation and migration of lung fibroblasts and IL-6 production 
are all key P2Y2R-mediated processes. These studies clearly demonstrate the involvement of 
P2Y2R subtypes in the pathogenesis of fibrotic lung diseases in humans and mice and support the 
development of selective P2Y2R antagonists for the treatment of idiopathic pulmonary fibrosis 
(IPF).7 To date, the only reported high affinity P2Y2R antagonists were those developed by 
scientists from AstraZeneca resulting in the non-nucleotide P2Y2R antagonist AR-C118925 (1).
8, 
9 
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Several in vivo and ex vivo studies using 1 have been reported further validating the therapeutic 
benefit of P2Y2R antagonists. Importantly, it has been shown that 1, which was reported to be 
inactive at 10 μM against a panel of 37 other receptors,  was able to concentration-dependently 
antagonize ATPγS-induced mucin secretion in an ex vivo model of human bronchial epithelial 
cells.10 In addition, Müller et al recently demonstrated that 1 was a selective, high affinity 
reversible antagonist of the P2Y2R.
11 
We were drawn to the exciting possibility of using 1 as a chemical template to design new P2Y2R 
antagonists12 and synthesize fluorescently labeled chemical tools to further probe P2Y2R 
function.13 Using fluorescence as a means to study GPCRs allows access to a large range of 
pharmacological techniques that can capture dynamic processes in living cells.14 In particular, 
fluorescently labeled receptor antagonists have been developed to target GPCRs allowing 
visualization of GPCR function at the cellular level.15–17  In addition, fluorescent ligands can be 
used in resonance energy transfer (RET) techniques, in particular those that utilize the luciferase 
NanoLuc, to quantify ligand-receptor interactions and determine the affinity of unlabeled 
ligands.18  This offers advantages for receptors such as P2Y2R for which there are currently no 
commercially available radio ligands.  In addition, as the reported antagonists for P2Y2R have mid 
to high affinity it is proposed that fluorescent ligands designed on these ligands might also have 
affinity in this range. This may prove problematic for techniques which directly monitor 
fluorescent ligand binding but  NanoBRET has been shown to display low non-specific binding at 
high fluorescent ligand concentrations.18, 19 
RESULTS AND DISCUSSION 
Synthesis and evaluation of hP2Y2R antagonists. The medicinal chemistry strategy involved an 
initial exploration of the structure activity relationship (SAR) around 1, to enable the design of 
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structural analogues with improved predicted physicochemical properties and to guide our design 
strategy through highlighting suitable linking sites to attach the fluorophore groups (Figure 1 and 
Table 1). 
 
Figure 1. SAR for P2Y2R antagonists showing changes from the furan in 1, to thiazole (reduced 
lipophilicity) and change from 2,8-dimethyl-5H-dibenzo[a,d][7]annulene to 7-chloro-4H-
benzo[5,6]cyclohepta[1,2-d]thiazole tricylic ring system.  
Table 1 The estimated affinity value for P2Y2R antagonists 1-6 obtained from the calcium 
mobilization assay 
Example hP2Y2 pKb
a Example hP2Y2 pKb
a 
1 7.51 ± 0.09 (12) 4 i.a. 
2b 6.43 ± 0.08 (3) 5 6.48 ± 0.10 (3) 
3 7.11 ± 0.14 (7)  6 5.99 ± 0.03 (7) 
 
a The estimated affinity value for each antagonist (pKb) was calculated from the shift of UTPS 
concentration response curve brought about by addition of a single concentration of antagonist 
using the Gaddum equation. i.a. = less than 50% inhibition of the response to 0.1M UTPS in the 
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presence of 10 M compound. UTPS EC50 = 7.9 ± 1.3 nM (n=25). b literature value pA2 5.78 Data 
shown is mean ± SEM, number of separate experiments given in parentheses. 
1 has previously been shown to have high lipophilicity (cLogP 4.2)20 and poor physicochemical 
properties for oral delivery.8 We therefore synthesized the thiazole analogue 3 (cLogP 3.8), with 
little loss of affinity for the P2Y2R. Replacement of the  2,8-dimethyl-5H-dibenzo[a,d][7]annulene 
to 7-chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazole tricylic ring gave 5 (pKb 6.5, clogP 3.4). 
21 In 
addition, non-parallel SAR was observed in the replacement of the N-1 thiouracil substituent with 
a methyl group to give a compound 6 with P2Y2R affinity, whereas the corresponding analogue 4 
proved inactive.  In order to explore this intriguing finding we synthesized a range of analogues of 
6 to study this SAR (Table 2).    
Table 2 Calcium mobilization activity for P2Y2R antagonists 6-19 
 
Example R3 hP2Y2 pKb
a 
7 NH2 6.56 ± 0.14 (4) 
8 PhNH i.a. (3) 
9 PhCH2NH i.a. (3) 
10 PhCH2CH2NH i.a. (3) 
11 1-methyl piperazin-4-yl i.a. (3) 
12 morpholinyl i.a. (3) 
13 piperidinyl i.a. (3) 
14 2-methoxyethan-1-aminyl 6.60 ± 0.21 (4) 
15 2-methoxypropan-1-aminyl 6.56 ± 0.09 (3) 
16 2-ethoxyethan-1-aminyl 6.73 ± 0.05 (3) 
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17 2-isopropoxyethan-1-aminyl 6.49 ± 0.09 (3) 
18 2-phenoxyethan-1-aminyl i.a. (3) 
19 phenyl i.a. (3) 
 
a The estimated affinity value for each antagonist (pKb) was calculated from the shift of the 
UTPS concentration response curve brought about by addition of a single concentration of 
antagonist using the Gaddum equation. i.a. = less than 50% inhibition of 0.1M UTPS response 
in the presence of 10 M compound (n=3). n.b. the corresponding uracil derivatives were inactive 
at 10 M compound. Data shown is mean ± SEM, number of separate experiments given in 
parentheses.   
From the SAR study of 6, it was shown that replacing thiazole 2-methyl substituent with an 
amino group increased hP2Y2R affinity (compare 6 with 7) whereas a sterically demanding 
substituent, such as 19 showed complete loss of affinity for the hP2Y2R. We therefore explored 
substitution of the amino group and showed that both sterically demanding amino groups (8, 9 and 
10) and cyclic tertiary amines (11, 12 and 13) were inactive. However the linear, less sterically 
demanding alkyl amino groups (14, 15, 16 and 17) increased hP2Y2R affinity, although the bulkier 
2-phenoxyethan-1-amino substituent 18 proved inactive.  
Thus far, all the compounds synthesized were tested as racemic mixtures. To try and determine 
whether the activity resided in one enantiomer, resolution of 14 and 16 was achieved through semi-
preparative chiral HPLC and the biology of the resolved enantiomers independently assessed 
(Table 3).  
Table 3 Calcium mobilization activity for resolved enantiomers of 14 and 15 
Example Racemic compound Enantiomeric excess (ee)a hP2Y2 Pkb
b 
20 
14 
99% 6.63 ± 0.11 (6) 
21 78% 5.82 ± 0.05 (3) 
22 16 95% i.a. (3) 
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23 96% 6.78 ± 0.05 (6) 
 
a Compounds separated using Phenomenex’s Lux 5 μm amylose-2 stationary phase. b The 
estimated affinity value for each antagonist (pKb) was calculated from the shift of UTPS 
concentration  response curve brought about by addition of a single concentration of antagonist 
using the Gaddum equation. i.a. = less than 50% inhibition of 0.1M UTPS response in the 
presence of 10 M compound (n=3). Data shown is mean ± SEM, number of separate experiments 
given in parentheses.   
 
From these results it is possible to see that the hP2Y2R antagonist affinity observed for the 
racemic compounds (14 and 16) resides largely in just one enantiomer 20 and 23 respectively. 
Although some antagonist activity is observed for 21, this may be attributed to residual active 
enantiomer 20 which constitutes 11% of the sample. Unfortunately, the resolved enantiomers 
proved to be amorphous powders and so single crystal X-ray determination of the absolute chirality 
could not be used for structural determination. However, vibrational circular dichroism of 22 and 
23 was used, where spectra were acquired on both samples and fitted to the calculated spectra.22–
24 The results (supplementary information) showed that there was a good match for 22 with the 
calculated spectrum for the (S)- enantiomer and therefore 23 was assigned as the active (R)- 
enantiomer (Figure 2). 
 
Figure 2. Chiral resolution of 16 and structural assignment made by vibrational circular dichroism. 
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In an attempt to increase affinity within the new series of compounds we incorporated key 
structural features of 14 and 5 to generate compound 24. 
 
However, 24 did not demonstrate the expected increase in affinity from combining the features of 
14 and 5 and showed a similar level of hP2Y2R affinity (pKd 7.02 ± 0.05,  n=4) to both 1 and 3, 
demonstrating non-additive SAR within the series of compounds.25 
 
 The synthesis of compounds 2-4 is illustrated in Scheme 1. Alkylation of 5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)pyrimidine-2,4(1H,3H)-dione8 with ethyl 2-(bromomethyl)thiazole-
4-carboxylate followed by treatment with Lawesson’s reagent and saponification gave 28 which 
was reacted with 2-amino tetrazole using benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate activation to afford 3. In a similar manner, alkylation with methyl iodide 
followed by conversion to the thiouracil gave 4, in good over all yield. 
 
Scheme 1. (a) (i) N,O-bis(trimethylsilyl)trifluoroacetamide, DCM, reflux, 18 h; (ii) ethyl 2-
(bromomethyl)thiazole-4-carboxylate, 50oC, 24 h (55%). (b) Lawesson’s reagent, 1, 4-dioxane, 
100oC, 18 h (85%). (c) NaOH, methanol/H2O, reflux, 1 h (91%). (d) 5-aminotetrazole, 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, DMF, DIPEA, rt, 1 h 
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(49%). (e) (i) N,O-bis(trimethylsilyl)trifluoroacetamide, DCM, reflux, 18 h; (ii). iodomethane, 
50oC, 24 h (61%). (f) Lawesson’s reagent, 1,4-dioxane, reflux, 18 h (40%). 
 
 
Scheme 2. Reagents and conditions: (a) Allyl alcohol, tetrabutylammonium chloride, DMF, 3% 
mol. palladium(II)acetate, NaHCO3, 50
oC, 18 h (92%). (b) (i) ethyl dichloroacetate, sodium 
ethoxide, diethyl ether, 30 min, 0-40oC; (ii) thioacetamide, ethanol, reflux, 3 h (30% over 2 steps). 
(c) NaOH, H2O/THF (1:1), rt, 18 h (99%). (d) (i) oxalyl chloride, cat. DMF, DCM, rt, 3 h; (ii) 
aluminium(III)chloride, DCM, rt, 18 h (39% over two steps). (e) Sodium tert-butoxide, THF, 0oC-
rt, 18 h (61%) (f) (i) n-butyllithium, THF, -78oC, 30 mins; (ii) 29, -78oC to rt, 1 h (65%). (g) 
trifluoroacetic acid, reflux, 72 h (36%). (h) (i) N,O-bis(trimethylsilyl)trifluoroacetamide, DCM, 
reflux, 18 h; (ii) iodomethane, 50oC, 24 h (61%). (i) Lawesson’s reagent, 1,4-dioxane, reflux, 18 
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h (40%). (j) (i) N,O-bis(trimethylsilyl)trifluoroacetamide, DCM, reflux, 18 h; (ii) ethyl 2-
(bromomethyl)thiazole-4-carboxylate, 50oC, 24 h (57%). (k) Lawesson’s reagent, 1, 4-dioxane, 
100oC, 18 h (89%). (l) (i) NaOH, methanol/H2O, reflux, 1 h (91%). (ii) 5-aminotetrazole, 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, DMF, DIPEA, rt, 1 h 
(30%). 
Scheme 2 shows the synthetic route to 5 and 6. The first step involved performing a Heck 
reaction, coupling 3-chloroiodobeneze 25 to allyl alcohol and this successfully isomerized in situ 
yielding the desired aldehyde 26. This was reacted with ethyl dichloroacetate in a Darzens 
condensation 25 to generate a -chloro epoxide which was reacted directly with thioacetamide to 
afford desired 2-methylthiazole 27 with moderate yields achieved over two steps. Freshly prepared 
sodium ethoxide, generated from sodium metal in dried ethanol was found to be the optimal base 
for the Darzens condensation. Saponification gave carboxylic acid 28 and treatment with oxalyl 
chloride generated the acyl chloride which was immediately cyclized to give the tricyclic ketone 
29 as a single regioisomer. Lithiation of the di tert-butyl ether-protected uracil 30,25 was readily 
achieved with n-butyllithium and this underwent a 1, 2-addition to ketone 29 to give tertiary 
alcohol 32. Concomitant deprotection and dehydration gave uracil 33 through heating in 
trifluoroacetic acid. Although the yield for this reaction was poor, other acidic conditions were 
ineffective. Alkylation at the N1-position of the uracil was achieved in a one-pot process of 
silylation with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), alkylation with iodomethane 
and subsequent desilylation to give 34. Finally, reaction with Lawesson’s reagent gave 6. From 
the uracil intermediate 33 alkylation with ethyl 2-(bromomethyl) thiazole-4-carboxylate26 gave 35 
which was subsequently reacted with Lawesson’s reagent to give 36. Hydrolysis was followed by 
reaction of the resulting carboxylic acid with 5-aminotetrazole and benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate to give 5. 
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Scheme 3. Reagents and conditions: (a) (i) Ethyl dichloroacetate, sodium ethoxide, diethyl ether, 
30 min, 0-40oC; (ii) thiourea, ethanol, reflux, 2.5 h (46% over 2 steps). (b) copper(II)chloride, tert-
butyl nitrite, acetonitrile, rt, 2 h (65%) (c) NaOH, H2O/THF (1:1), rt, 18 h (quant.). (d) (i) Oxalyl 
chloride, cat. DMF, DCM, rt, 3 h; (ii) AlCl3, DCM, rt, 18 h (83% over two steps). (e) (i). 31, n-
butyllithium, THF, -78oC, 30 mins; (ii). 82, -78oC to rt, 1 h (79%). (f) 1:1 acetic acid/1,4-dioxane 
140oC,10 min (58%). (g) (i) N,O-bis(trimethylsilyl)trifluoroacetamide, DCM, reflux, 18 h; (ii). 
iodomethane, 50oC, 24 h (61%) (h) Phenylboronic acid, Na2CO3, 1% mol. bis(triphenylphosphine) 
palladium(II)chloride, 1,4-dioxane, water, MW, 1500C, 5 min (68%). (i)  Lawesson’s reagent, 1,4-
dioxane, reflux, 18 h (76%). (j) R1R2NH, 1, 4-dioxane, MW, 100
oC, 4h (51-92 %). (k) Lawesson’s 
reagent, 1,4-dioxane, reflux, 18 h (44-88%). (l) (a) (i) N,O-bis(trimethylsilyl)trifluoroacetamide, 
1,2-dichloroethane, reflux, 18 h; (ii) ethyl 2-(bromomethyl)thiazole-4-carboxylate, reflux, 48 h 
(91%). (m) 2-Methoxyethyl amine, triethylamine, 1, 4-dioxane, reflux, 72 h (59%). (n) Lawesson’s 
reagent, 1, 4-dioxane, reflux, 18 h (81%). (o) (i) NaOH, methanol/H2O, reflux, 1 h (91%). (ii) 5-
Aminotetrazole, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, DMF, 
DIPEA, rt, 2 h (34%). 
In a similar sequence to Scheme 2, aldehyde 26 was reacted with ethyl dichloroacetate and the 
resulting crude -chloro epoxide reacted with thiourea to afford the 2-aminothiazole 37 which was 
converted to the 2-chlorothiazole 38 (Scheme 3). The ethyl ester was hydrolyzed to afford 
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carboxylic acid 39, converted to the acid chloride and cyclized to tricyclic ketone 40. Lithiation of 
the tert-butyl ether-protected uracil 31 and reaction with 40 gave the tertiary alcohol 41. After 
screening a range of milder acidic conditions, heating to 140oC with MW irradiation in 1:1 acetic 
acid/1,4-dioxane for 10 minutes was found to be optimal for the formation of the desired uracil 
intermediate 42, which was subsequently methylated to give 43. The chlorine atom in compound 
43 was readily displaced through nucleophilic aromatic substitution with a range of primary and 
secondary amines on heating under basic conditions. These conditions were unsuccessful when 
using aniline and, in this instance, heating in the microwave with hydrochloric acid (catalytic) 
proved successful to give 46. Microwave-based conditions were employed for the substitution with 
ammonia in the synthesis of 45. A Suzuki reaction with phenylboronic acid gave 44. Using 
Lawesson’s reagent, it was then possible to convert these uracil derivatives (44-54) to the 
respective 4-thiouracil derivatives (6-19). Employing a route analogous to the synthesis of 
compound 7, it was possible to generate the desired tetrazole analogue 24. Uracil intermediate 42 
was alkylated at the N1-position with ethyl 2-(bromomethyl)thiazole-4-carboxylate to give 57.  
This was reacted with 2-methoxyethylamine to afford 58, which was subsequently reacted with 
Lawesson’s reagent to give the 4-thiouracil 59. Hydrolysis, followed by benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate activation and reaction with 5-
aminotetrazole, afforded 24. 
Synthesis of hP2Y2R fluorescent ligands. With a view to developing a series of fluorescent 
conjugates suitable for both a bioluminescence resonance energy transfer (BRET) ligand binding 
assay 18,27–29 and imaging through confocal microscopy, we embarked on a strategy to synthesize 
bodipy conjugates, specifically dyes bodipy A (absorption max 628 nm, emission max 642 nm) or 
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bodipy B (absorption max 503 nm,  emission max 509 nm) as this would allow us the opportunity 
of ligand choice in future imaging work. 
Two positions on to the P2Y2R antagonist core structure were considered for attachment of the 
linker and fluorophore (Figure 3). In order to simplify the synthetic chemistry and increase SAR 
within the series, we examined replacement of the furan ring of 1 and the thiazole ring of 2 with a 
1,3,5 tri-substituted phenyl ring. This would allow attachment of the acyl tetrazole group in 
addition to providing a second free carboxylic acid group to attach the fluorescent conjugates. 
Fortunately, the 3,5-dicarboxylic acid 60 (hP2Y2R pKd 6.53 ± 0.04, n= 7) was well tolerated with 
no loss of affinity for the P2Y2R compared with compound 2. Therefore, the first series of 
compounds have the linker-fluorophore attached via the phenyl ring of 60.  
 
Having established that alkoxyalkyl amines are tolerated for activity in the 2-position of the 
thiazole in the 4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl) tricyclic ring of compounds of the 
type shown in Figure 2, this position was chosen as the second point of attachment of the linker-
fluorophore. Finally, a third generation of fluorescent ligands would be explored containing the 
optimal second generation fluorescent ligand with incorporation of the acyl tetrazole functional 
group. 
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Figure 3. Design of fluorescent P2Y2R antagonists based from SAR on 1. The figure shows 
potential attachment points from which to attach either bodipy A or bodipy B via a suitable linking 
group selected. * Represents attachment points for fluorophore linkage via a suitable linking group. 
 
First generation hP2Y2R fluorescent ligands. The general synthetic route to the first generation 
P2Y2R fluorescent antagonists is shown in Scheme 4. 
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Scheme 4. a) Dimethyl 5-(bromomethyl)isophthalate, BSTFA, 1,2-dichloroethane, reflux, 16 h. 
b) Lawesson’s reagent, 1,4-dioxane, reflux, 16 h. c) 2eq NaOH, MeOH, toluene, H2O, 4h. 65% (3 
steps) d) tert-butyl (2-(2-aminoethoxy)ethyl)carbamate (53%) or tert-butyl (2-
aminoethyl)carbamate (63%), NEt3, benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate, DMF, rt, 0.5 h. e) LiOH, MeOH, H2O, 16 h, rt. 14-30%. f) 4-aminotetrazole, 
NEt3, Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, DMF, 1h, rt. g) 4M 
HCl in 1,4-dioxane, 1h. h) bodipy-SE, DIPEA, DMF, rt, 1-4 h.15-45%. 
 
Alkylation of 5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)pyrimidine-2,4(1H,3H)-dione8 
with dimethyl 5-(bromomethyl)isophthalate, followed by treatment with Lawesson’s reagent and 
selective hydrolysis of one of the methyl esters gave 61. The carboxylic acid 61 was activated 
using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate and coupled to form 
the appropriate amide (62-63). The second ester was then hydrolyzed and converted to the 
amidotetrazoles (64-65). Finally, the Boc protecting group was removed and the resulting amine 
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coupled to the fluorophore using the appropriate commercially available BODIPY succinimidyl 
ester to give a small library of 4 fluorescent conjugates (66-69). 
To determine whether any of these conjugates had affinity at the P2Y2R and consequently if 
they could be used in NanoBRET binding assays, a 1321N1 astrocytoma cell-line expressing 
recombinant P2Y2R tagged on its N-terminus with NanoLuc (NanoLuc-P2Y2R) was generated. 
The NanoLuc-tagged P2Y2 receptors exhibited normal calcium signals (EC50 for UTPS of 91 ± 
12 nM; n=3).  These NanoLuc-P2Y2 cells were treated with increasing concentrations of 66-69 
and then treated with the NanoLuc substrate furimazine, before the resulting BRET signal was 
monitored. All four compounds showed moderate to low affinity for the NanoLuc-P2Y2R (Table 
4), with the conjugates 68 and 69 having the higher affinities.  However, this did illustrate the 
power of using NanoBRET to monitor ligand binding to low affinity receptors. 
Table 4: Affinity of 66, 67, 68 and 69 determined in 1321N1 astrocytoma cells expressing 
recombinant NLuc-P2Y2R  
Example nb Rc NanoBRET pKd
a 
66 0 A 5.56 ± 0.1 (3) 
67 0 B 5.78 ± 0.18 (3) 
68 1 A 6.12 ± 0.07 (3) 
69 1 B 6.07 ± 0.15 (3) 
apKd values derived from saturation binding curves. 
b, c n and R previously defined from Scheme 
4. Data shown is mean ± SEM, number of separate experiments given in parentheses. 
 
Second generation hP2Y2R fluorescent ligands. The general synthetic route to the second 
generation P2Y2R fluorescent antagonists, in which the linker-fluorophore is attached to the 
thiazole ring, is illustrated in Scheme 5. 
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Scheme 5. Reagents and conditions: (a) amine, NEt3, 1,4-dioxane, reflux, 72 h. 96-97% (b) 
Lawesson’s reagent, 1,4-dioxane, 100oC, 18 h. 39-74% (c) TFA, DCM, rt, 30 min. (d) amine, 
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, DMF, DIPEA, rt, 1 h. 36-
58% (2 steps) (e)  TFA, DCM, rt, 30 min; f) bodipy-SE, DIPEA, DMF, rt, 1-4 h. 10-54% (2 steps). 
 
Nucleophilic displacement of the 2-chloro substituent of 43 by either tert-butyl 3-
aminopropanoate or tert-butyl 6-aminohexanoate gave the corresponding tert-butyl esters (70 and 
71). Treatment with Lawesson’s reagent in 1,4-dioxane at 100oC resulted in formation of the 4-
thiouracils (72 and 73). The carboxylic acids were generated from the tert-butyl esters using TFA-
mediated hydrolysis and subsequently coupled with tert-butyl (2-aminoethyl)carbamate or tert-
butyl (2-(2-aminoethoxy)ethyl)carbamate to generate the corresponding amides (74-77). The Boc 
protecting group was removed using TFA and the resulting amines coupled with the appropriate 
commercially available bodipy-succinimidyl ester (SE), generating a small library of 14 
fluorescent conjugates (78-91). These fluorescent conjugates were initially tested using the 
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aforementioned NanoBRET binding assay at fixed concentrations of 10 µM in the presence and 
absence of 10 µM 1 (see figure S1 in the supplementary material). It was found that 80, 85, 86 and 
87 generated the largest specific NanoBRET signal, therefore their affinity was determined from 
saturation binding assays demonstrating the excellent signal to noise ratios observed from the 
NanoBRET assay even for low affinity conjugates (Figure 4; Table 5).  
 
Figure 4. NanoBRET saturation binding isotherm determined in 1321N1 astrocytoma cells 
expressing recombinant NLuc-P2Y2R. This has been performed for (a) 80, (b) 85, (c) 86 and (d) 
87 in the absence and presence of 10 µM 1. Data points are mean values ± SEM (n= 3 or 4). 
Table 5. Affinity of 85, 86, 87 and 80 determined in 1321N1 astrocytoma cells expressing 
recombinant NLuc-P2Y2R  
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Example pKd 
80 5.29  0.17 (4) 
85  4.91  0.14 (4) 
86  5.67  0.10 (4) 
87 5.38  0.19 (3) 
pKd values derived from saturation binding curves. Data shown is mean ± SEM, number of 
separate experiments given in parentheses. 
 
Reassuringly, the affinities determined for the non-fluorescent P2Y2R antagonist 1, with either 
86 (pKi 7.45  0.13, n = 4) or 87 (pKi 7.32  0.13, n = 4) where consistent with the affinity 
determined using the P2Y2R functional assay (pKb 7.51 ± 0.09); demonstrating that the P2Y2R 
fluorescent ligands could be used in a NanoBRET assay for determining the affinity of non-
fluorescent P2Y2R antagonists. The clear demonstration of saturable specific binding with these 
low affinity fluorescent ligands confirmed the utility of the NanoBRET binding format and the 
ability to exploit the good signal to noise ratio of this proximity-based assay. To explore the 
opportunity to develop higher affinity fluorescent conjugates, we embarked on a synthetic strategy 
to incorporate the affinity-enhancing acyl-tetrazole functional group into the fluorescent 
compounds. 
Third generation P2Y2R fluorescent ligands. The general synthetic route to the third generation 
P2Y2R fluorescent antagonists is illustrated in Scheme 6.  Displacement of the chlorine atom in 
compound 57 with tert-butyl 3-aminopropanoate gave tert-butyl ester 92.  Treatment with TFA 
afforded conversion of the tert-butyl ester to the corresponding acid which was immediately 
activated and coupled to tert-butyl (2-aminoethyl)carbamate 93 using HATU. Hydrolysis of the 
ethyl ester, activation of the carboxylic acid using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate and coupling with 5-aminotetrazole gave the 
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amidotetrazole 94. The Boc protecting group was removed and the resulting amine attached to the 
fluorophore using the appropriate bodipy succinimidyl ester (Scheme 6). 
 
Scheme 6. Reagents and conditions: (a) amine, NEt3, 1,4-dioxane, reflux, 72 h. (89%). (b) 
Lawesson’s reagent, 1,4-dioxane, reflux, 18 h (48%). (c) TFA, DCM, rt, 30 min (55%). (d) tert-
butyl (2-aminoethyl)carbamate, HATU, DCM, DIPEA, rt, 24 h (63%). (e) 1. NaOH, MeOH, 
reflux, 4 h; 2. 5-aminotetrazole, Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate, DIPEA, DMF, rt 4 h (28% over 2 steps). (f) 1. TFA, DCM, rt, 30 min; 2. 
bodipy-SE, DIPEA, DMF, rt, 1-4 h. (11-18%, 2 steps). The structures of compounds 95-98 are 
assigned in table 6. 
 
In contrast to non-fluorophore compounds, 14 and 24 where there was little change in affinity 
in changing the uracil N1-substituent, in three of the four compounds (95-98) there was a 
significant increase in affinity relative to the non-amidotetrazole series - compare 98 & 86, 96 & 
85 and 97 & 80 (Table 5 and Table 6).  
Table 6. Affinity of 95, 96, 97 and 98 determined in 1321N1 astrocytoma cells expressing 
recombinant NLuc-P2Y2R  
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Example mb Rc NanoBRET pKd
a 
95 0 A 6.05 ± 0.12 (3) 
96 0 B 7.05 ± 0.05 (3) 
97 1 A 6.89 ± 0.06 (7) 
98 1 B 6.32 ± 0.10 (17) 
apKd values derived from saturation binding curves 
b, c m and R previously defined from Scheme 
6. Data shown is mean ± SEM, number of separate experiments given in parentheses. 
 
Pharmacological evaluation of third generation P2Y2R fluorescent ligands. To further evaluate 
the utility of fluorescent ligands to study the pharmacology of the P2Y2R, one bodipy A (97) and 
one bodipy B (98) linked fluorescent ligand was chosen for further studies. Initially, we confirmed 
that 97 and 98 still retained the ability to functionally antagonize the P2Y2R (Figure 5).  In the 
Ca2+ mobilization assay, a modest rightwards shift of the agonist dose-response curve was 
observed for both 10M 97 (pKb 5.69 ± 0.05, n=8) and 10M 98 (pKb 5.87 ± 0.05, n=7).  
 
Figure 5. Pharmacological evaluation of: 97 and 98 showing the effect on Ca2+ mobilization in 
hP2Y2R-1321N1 cells induced by 0.1 M UTPS (n=7 or 8). 
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Compounds 97 and 98 bought about a clear concentration-dependent increase in the BRET ratio 
in the NLUC-tagged hP2Y2R assay (Figure 6).  This was antagonized by 1 (Figures 6 c & d) 
yielding pKi values of 7.66 ± 0.11 (n = 9) and 7.38 ± 0.04 (n = 6) for antagonism of 97 and 98 
binding respectively.  
 
Figure 6. Pharmacological evaluation of: a) 97 and b) 98 showing BRET saturation binding (n=7); 
c) and d) Displacement of 97 (c) (100nM, n=9) and 98 (d) (1µM, n=6) binding in NLuc-P2Y2 
1321N1 cells by 1.  Values show Mean ± SEM. 
To further evaluate the utility of the fluorescent conjugate 98 in the NanoBRET-ligand binding 
assay the affinity of a selection of P2Y2R antagonists (1, 3, 6, 22, 23, 60, 86) and the previously 
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reported stabilized triphosphate P2Y2R antagonist 99
8 over a range of P2Y2R affinity were 
determined in competition binding experiments. 
 
 All eight compounds induced a concentration dependent decrease in specific binding of 98 that 
enabled their affinity to be determined. There was a good correlation in the values obtained in the 
NanoBRET assay to those determined in the Ca2+ mobilization assay (Table 7).  In addition to 
antagonists, the NanoBRET assay was also used to estimate the affinity of UTPγS. As there has 
been no reports of radioligands for the P2Y2R, this measurement has not previously been possible.   
Table 7. Comparison of affinity estimates obtained in Ca2+ mobilization and NanoBRET assays 
Example pKb Ca
2+ mobilizationa pKi NanoBRET (98)
b  
1 7.51 ± 0.09 (12) 7.38 ± 0.04 (6) 
3 7.11± 0.14 (7) 6.89 ± 0.05 (6) 
6 5.99 ± 0.03 (7) 5.81 ± 0.10 (6) 
22 <5.0 (6) 5.28 ± 0.05 (3) 
23 6.74 ± 0.10 (6) 6.56 ± 0.16 (3) 
60 6.53 ± 0.04 (7) 6.84 ± 0.02 (6) 
86 6.30 ± 0.05 (6) 6.40 ± 0.01 (6) 
99 6.59 ± 0.12 (3)c 7.08  ± 0.03 (3) 
UTPS ND  5.46 ± 0.04 (6) 
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a The estimated affinity value for each antagonist (pKb) was calculated from the shift of the 
agonist dose response curve brought about by addition of a single concentration of antagonist using 
the Gaddum equation. b Measured in competition binding experiment using fluorescent ligand 98. 
c reported pA2 8.0
8. ND = not determined due to agonist activity. Data shown is mean ± SEM, 
number of separate experiments given in parentheses. 
 
The availability of both a green (98) and a red (97) fluorescent P2Y2R ligand with reasonable 
affinity for the hP2Y2R suggested that they may both have utility for imaging of the receptor in 
living cells.  Confocal microscope images of fluorescent ligands 97 and 98 with astrocytoma 
1321N1 cells expressing hP2Y2R (Figures 7a and c) showed localized membrane fluorescence and 
very little intracellular fluorescence. When cells were pretreated with 1, the specific-membrane 
fluorescence of 97 and 98 was substantially reduced (Figures 7b and d), indicating that the majority 
of the membrane fluorescence observed was specific labeling of the P2Y2R. 
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Figure 7. Visualization of the binding of 97 (a) and 98 (c) on astrocytoma cells expressing 
hP2Y2R. In each case, the images in the left hand column shows a confocal image with 100 nM of 
the fluorescent ligand, while the right hand column shows the images (b) and (d) with the addition 
of 10 M of 1. In all conditions, cells were incubated for 30 min at 37°C in the presence or absence 
of 10 M of 1. Single equatorial confocal images were then obtained in the continued presence of 
the fluorescent ligand (97 or 98) and/or unlabeled antagonist. Images shown are from a single 
experiment representative of 4 performed. 
CONCLUSION 
We have described the synthesis and evaluation of new examples of acidic hP2Y2R antagonists 
based on the known hP2Y2R antagonist 1. In addition, we have shown the discovery of a new 
series of neutral hP2Y2R antagonists and demonstrated SAR leading to the identification of potent 
hP2Y2R antagonists (such as 20 and 23). In addition, we have shown a stereochemical preference 
for biological activity within this series as typified by the resolved examples 20 & 21 and 22 and 
23. Vibrational circular dichroism has suggested that, in the case of 16 all hP2Y2R biological 
activity resides in the (R)-enantiomer 23 – although single crystal X-ray work will be required to 
confirm this initial stereochemical assignment. The SAR studies led to the identification of suitable 
linking sites for attachment of the fluorescent ligand to generate three distinct series of 
fluorescently-labelled hP2Y2R antagonists. From this extensive synthetic work, two examples (97 
and 98) were identified demonstrating both functional antagonist activity (Ca2+ mobilization assay) 
and sufficient affinity for the hP2Y2R through a new bioluminescence resonance energy transfer 
(BRET) assay. In addition, confocal microscopy revealed clear, displaceable membrane labeling 
of astrocytoma cells expressing the hP2Y2R. The excellent imaging properties, make 97 and 98 
ideal tools for studying hP2Y2R distribution and organization. Finally, the discovery of the new 
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hP2Y2R antagonist fluorescent ligands (97 and 98) became realized as a result of an extensive 
program of synthetic chemistry where it proved essential to explore the parallel changes of linker 
attachment points, fluorophores and linking group.30 From this study, only a very few fluorescent 
conjugates were shown to possess sufficient affinity to enable the establishment of a new 
NanoBRET-based fluorescent assay for the identification of new hP2Y2R fragments and ligands.    
EXPERIMENTAL SECTION 
CHEMISTRY - GENERAL METHODS 
Chemicals and solvents were provided by Fisher Scientific UK, Acros Organics, Sigma-Aldrich, 
Merck Millipore or Fluorochem. BODIPY®FL-X-NHS (D6102) and BODIPY®630/650-X-NHS 
(D10000) were purchased from Molecular Probes (Invitrogen, UK). All reactions were monitored 
by TLC using Merck Silica Gel 60Å F254 TLC plates or by LC-MS. Unless otherwise stated, all 
compounds were dried under high vacuum either at rt or within an oven at 40oC. LC-MS data was 
collected on a Shimadzu UFLCXR HPLC system coupled to an Applied Biosystems API 2000 
LC/MS/MS electrospray ionization (ESI). The column used was a Phenomenex Gemini-NX 3 μm-
110Â C18, 50x2mm at 40ºC. The flow rate was 0.5 mL/min, the UV detection was at 220 nm and 
254 nm. Method 1 for the LC-MS ran for 1 min at 5% B; 5 to 98% B over 2 min, 98% B for 2 min, 
98 to 5% B over 0.5 min and then 5% for 1 min. Method 2 for the LC-MS ran for 1.5 min at 10% 
B; 10 to 98% B over 8 min; 98% B for 2 min; 98 to 10% B over 0.5 min and then 10% B for 1 
min. Where solvent A: 0.1% formic acid in water; solvent B: acetonitrile. Unless otherwise stated 
compounds reported had a purity >95% at the wavelength and method quoted. HRMS data was 
collected on a Bruker microTOF II mass spectrometer using electrospray ionization (ESI-TOF). 
Adducts within error of ±10 ppm are reported. Preparative RP-HPLC was performed on a Waters 
2767 sample manager coupled to Waters 2525 binary gradient module and a Waters 2457 dual 
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wavelength absorbance detector. The column used was a Phenomenex Gemini® 5 μm NX C18 
110 Å, 150x21 mm at ambient temperature. The flow rate was 40 mL/min, the UV detection was 
at 254 nm. Method 3 for the preparative RP-HPLC ran for 1 min at 10% B; then 10 to 35% B over 
4 min; then 35 to 40% B over 20 min; then 40 to 90% B over 2 min; then 90 to 10% B over 2 min 
and then for 1 min at 10% B. Method 4 for the preparative RP-HPLC ran for 1 min at 10% B; 10 
to 45% B over 4 min; 45 to 50% B over 20 min; 50 to 90% B over 2 min; 90 to 10% B over 2 min 
and then for 1 min at 10% B. Where solvent A was 0.1% trifluoroacetic acid in water and solvent 
B was 0.1% trifluoroacetic acid in acetonitrile. Chiral-HPLC was performed on a Dionex ICS-
3000 SP single pump coupled to a Rheodyne 9725i PEEKinjector coupled to a Dionex UltiMate 
3000 Variable Wavelength Detector. The columns used were Phenomenex Lux® 5 μm Amylose-
2, 250 x 4.6 mm and 250 x 10 mm; for analytical and semi-preparative runs respectively. These 
operated at ambient temperature and, unless otherwise stated, the mobile phase was 25% 
ethanol/hexane with a flow rate of 1 mL/min for analytical runs and 5 mL/min for semi-preparative 
runs. The UV detection was at 254 nm. NMR spectroscopy was performed using a Bruker AV(III) 
HD 400 NMR spectrometer equipped with a 5 mm BBFO+ probe, recording 1H and 13C NMR at 
400.25 MHz and 100.66 MHz respectively; or a Bruker AV(III) 500 NMR spectrometer equipped 
with a 5 mm dual 1H/13C helium-cooled cryoprobe, recording 1H and 13C NMR at 500.13 MHz 
and 125.77 MHz respectively. NMR data was processed using iNMR (version 5.5.7) referencing 
spectra to residual solvents. Chemical shifts are quoted as δ: values in ppm; coupling constants J 
are given in Hz and multiplicities are described as follows: s - singlet, d - doublet, t - triplet, q - 
quartet, qi - quintet, sep – septet, m – multiplet, app – apparent, br - broad.  
Non standard abbreviations used in experimental: BODIPY® (boron-dipyrromethene); Calcd. 
(calculated); ESI (electrospray ionization); FC (flash chromatography); HPLC (high performance 
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liquid chromatography); HRMS (high resolution mass spectrometry); LC-MS (liquid 
chromatography mass spectrometry); MW (microwave); PREP (preparative); RM (reaction 
mixture); RP (reverse phase); TLC (thin layer chromatography). 
All compounds submitted for biological screening had a purity >95%. 
General Procedure 1 – Substitution of 2-chlorothiazole to generate 2-aminothiazoles 
A stirred solution of 43 (0.15-0.50 mmol) dissolved in anhydrous 1,4-dioxane (0.1 M, 1.5-5.0 
mL) was treated with a chosen amine (4 eq., 0.45-2.00 mmol) and triethyl amine (10 eq. 1.50-5.00 
mmol) under N2 and heated either to reflux for 36-72 h until completion was observed by TLC or 
LC-MS or heated in a microwave reactor at 100oC for 4 h. The reaction mixture was concentrated 
in vacuo directly onto silica gel and purified by chromatography on silica gel (2-5% MeOH/DCM 
w.0.1% 880 NH3) to afford the desired 2-aminothiazoles 45-56. 
General Procedure 2 – Thionation of uracils to 4-thiouracils using Lawesson’s reagent.  
A stirred suspension/solution of the uracil (0.05-0.25 mmol) and Lawesson’s reagent (2 
stoichiometric eq./1 molar eq., 0.05-0.25 mmol) in anhydrous 1,4-dioxane (0.05 M, 1-5 mL) were 
heated to reflux (1200C) under N2 for 18 h generating deep yellow/orange solutions. These were 
allowed to cool to room temperature and the crude reaction mixture concentrated in vacuo onto 
silica gel and, unless otherwise stated, the title compound purified by chromatography on silica 
gel eluting with (0-5% MeOH/DCM) to afford the desired 4-thiouracil. 
General Procedure 3 - Synthesis of BODIPY® labelled, fluorescent conjugates. 
A solution of the Boc–protected amine (2.00 μmol) dissolved in DCM (0.50 mL) was treated 
with TFA (0.25 mL) and stirred at RT for 30 min. This was then diluted with toluene (10 mL) and 
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concentrated in vacuo to 1/5th volume; this was repeated 3 times before concentrating to dryness 
to afford the TFA salt of the conjugate. This was dissolved in DMF (500 μL), treated with DIPEA 
(25 μL), followed by a solution of either BODIPY®FL-X-NHS (1.00 mg, 2.00 μmol) in DMF (150 
μL); BODIPY®630/650-X-NHS (1.32 mg, 2.00 μmol) in DMF (150 μL); or a solution of 
BODIPY®FL-NHS or BODIPY®630/650-NHS;  generated in situ by mixing BODIPY®FL-CO2H 
X (0.78mg,  2.00 μmol) or BODIPY®630/650-CO2H (0.90mg, 2.00 μmol) with HATU (0.76 mg, 
2.00 μmol), NHS (0.23 mg, 2.00 μmol) and DIPEA (25 μL) in DMF (150 μL) for 30 min before 
addition. These were then allowed to react at room temperature in the absence of light for 1-4 h 
until, completion observed by LC-MS, and then purified directly from the reaction mixture by 
preparative reverse phase HPLC to afford the desired fluorescent conjugate after lyophilization. 
2-((5-(2,8-Dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-carboxamide (3). 
PyBrop® (0.046 g, 0.1 mmol) was added to a stirred solution of 2-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)thiazole-4-
carboxylic acid (2) (0.04 g, 0.082 mmol), 5-aminotetrazole monohydrate (0.018 g, 0.18 mmol) and 
triethylamine (0.036 g, 0.36 mmol) in DMF (1 mL). After 10 minutes the reaction mixture was 
partitioned between 1M hydrochloric acid and ethyl acetate. The ethyl acetate solution was washed 
with water and brine and evaporated to dryness. Purification was by silica gel chromatography 
eluting with ethyl acetate:methanol:acetic acid, 93:5:2. Yield 0.025 g, 0.049 mmol, 49% as a 
yellow solid. 1H NMR (400 MHz, DMSO) δ 12.73 (s, 1H), 12.17 (s, 1H), 11.96 (s, 1H), 8.74 (s, 
1H), 7.46 (d, J = 7.8 Hz, 2H), 7.14 (ddd, J = 7.7, 1.9, 0.8 Hz, 2H), 7.10 (s, 2H), 7.08 (s, 1H), 6.75 
(s, 2H), 5.75 (s, 1H), 5.25 (s, 2H), 2.23 (s, 6H). Rt 3.02 (254nm); (m/z): 555.0 (M+1). 
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5-(2,8-Dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-1-methyl-4-thioxo-3,4-
dihydropyrimidin-2(1H)-one (4) was prepared using the procedures for 34 and 6, using 5-(2,8-
dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)pyrimidine-2,4(1H,3H)-dione (0.14 g, 0.42 mmol). 
Yield 0.08 g, 0.2 mmol, as a yellow solid, 48% over the two steps. 1H NMR (400 MHz, DMSO) δ 
12.53 (s, 1H), 7.47 (d, J = 7.8 Hz, 2H), 7.20 (s, 2H), 7.16 (ddd, J = 7.8, 1.9, 0.8 Hz, 2H), 7.01 (s, 
1H), 6.95 (s, 2H), 5.82 (s, 1H), 3.17 (s, 3H), 2.29 (s, 6H). Rt 2.87 (254nm); (m/z): 361.4 (M+1) 
2-((5-(7-Chloro-2-methyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-carboxamide (5). A 
stirred solution of 36 (65 mg, 0.120 mmol) in MeOH (10 mL) was treated with 2M NaOH (0.18 
mL, 0.36 mmol) and heated to reflux for 30 min under N2. Completion was observed by TLC and 
the RM concentrated to 1/3rd volume, diluted with ethyl acetate (20 mL), washed with 1M HCl (10 
mL),  brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo to afford the 
corresponding acid as an orange solid (60 mg). A stirred solution of the acid (30 mg, 0.058 mmol) 
in DMF (3 mL) was treated with DIPEA (40μL) and 5-aminotetrazole monohydrate (12 mg, 0.117 
mmol) followed by PyBroP® (41 mg, 0.087 mmol) and stirred at rt for 2 h. until completion was 
observed by LC-MS. The RM was quenched with water (c.a. 2 drops), diluted with ethyl acetate 
(20 mL), partitioned with 1M HCl (10 mL) and the organics extracted with ethyl acetate (2 x 10 
mL), combined washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo 
azeotroping DMF with toluene (3 x 50 mL) to afford an orange oil. This was purified by washing 
with 10% MeOH/DCM before eluting off the desired compound with 10% MeOH/DCM w. 1% 
acetic acid affording the title compound 5, an orange solid (10 mg, 0.017 mmol, 30%). LC-MS 
(ESI+) Rt: 2.79 min (254 nm, Method 1); (m/z): 581.9 [M(35Cl)+H]+ H.MS-TOF (ESI-) (m/z): [M-
H]- calcd. for C23H15ClN9O2S3, 580.0205; found, 580.0186. 
1H NMR (500 MHz, DMSO-d6) δ: 
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12.90 (s, 1H), 8.50 (s, 1H), (d, J = 8.4 Hz, 1H), 7.66 (s, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.42 (dd, J 
= 8.4, 2.3 Hz, 1H), 7.06 (s, 2H), 6.53 (s, 1H), 5.36 (d, J = 15.7 Hz, 1H), 5.30 (d, J = 15.7 Hz, 1H), 
2.59 (s, 3H) (N.B, -CONH & Tetrazole-NH not observed). 
5-(7-Chloro-2-methyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-thioxo-3,4-
dihydropyrimidin-2(1H)-one (6). Following General Procedure 2, 34 (60 mg, 0.161 mmol) was 
converted to the title compound 6 which was isolated at 1% MeOH/DCM, a yellow solid (25 mg, 
0.065 mmol, 40%). LC-MS (ESI+) Rt: 2.85 min (254 nm, Method 1); (m/z): 388.1 [M(35Cl)+H]+. 
1H NMR (400 MHz, CDCl3) δ: 9.39 (s, 1H), 7.70 (d, J = 8.3 Hz, 1H), 7.38 (dd, J = 8.3, 2.2 Hz, 
1H), 7.35 (d, J = 2.1 Hz, 1H), 7.19 (s, 1H), 6.95 (d, J = 11.6 Hz, 1H), 6.91 (d, J = 11.6 Hz, 1H), 
6.22 (s, 1H), 3.33 (s, 3H), 2.72 (s, 3H). 13C NMR (101 MHz, CDCl3) δ: 188.4, 166.9, 151.1, 147.9, 
140.4, 135.7, 134.0, 132.7, 132.5, 130.7, 129.9, 129.3, 129.1, 120.3, 119.2, 45.9, 37.0, 19.4. 
5-(2-Amino-7-chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-thioxo-3,4-
dihydropyrimidin-2(1H)-one (7). Following General Procedure 2, 45 (45 mg, 0.121 mmol) was 
converted to the title compound 7 and isolated at 2% MeOH/DCM as a yellow solid (4.8 mg, 0.012 
mmol, 10%). LC-MS (ESI+) Rt: 2.51 min (254 nm, Method 1); (m/z): 389.0 [M(35Cl)+H]+ 
5-(7-Chloro-2-(phenylamino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-
thioxo-3,4-dihydropyrimidin-2(1H)-one (8). Following General Procedure 2, 46 (45 mg, 0.100 
mmol) was converted to the title compound 8 which was isolated at 2% MeOH/DCM, a yellow 
solid (39 mg, 0.084 mmol, 84%). LC-MS (ESI+) Rt: 3.06 min (254 nm, Method 1); (m/z): 465.2 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ:  12.73 (s, 1H), 10.38 (s, 1H), 7.94 (s, 1H), 7.59 
(dd, J = 8.7, 1.1 Hz, 2H), 7.55 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 2.3 Hz, 1H), 7.39 (dd, J = 8.4, 2.3 
Hz, 1H), 7.35 (dd, J = 8.6, 7.4 Hz, 2H), 7.03 (d, J = 11.7 Hz, 1H), 7.00 (d, J = 11.7 Hz, 1H), 7.02-
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6.98 (m, 1H), 5.74 (s, 1H), 3.39 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 189.4, 164.0, 155.2, 
148.5, 148.4, 144.5, 141.0, 137.6, 134.7, 130.9, 129.5, 128.9, 128.5, 128.2, 122.4, 122.3, 118.2, 
117.8, 117.4, 44.7, 37.3. 
5-(2-(Benzylamino)-7-chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-
thioxo-3,4-dihydropyrimidin-2(1H)-one (9). Following General Procedure 2, 47 (30 mg, 0.065 
mmol) was converted to the title compound 95 which was isolated at 2% MeOH/DCM, a yellow 
solid (25 mg, 0.053 mmol, 81%). LC-MS (ESI+) Rt: 3.01 min (254 nm, Method 1); (m/z): 478.9 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.65 (s, 1H), 8.42 (t, J = 5.8 Hz, 1H), 7.63 (s, 
1H), 7.54 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.34-7.30 (m, 5H), 7.27-7.24 (m, 1H), 6.86 
(s, 2H), 5.69 (s, 1H), 4.48 (dd, J = 15.3, 5.9 Hz, 1H), 4.41 (dd, J = 15.3, 5.6 Hz, 1H), 3.26 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δ: 189.2, 169.5, 148.8, 148.5, 143.5, 139.0, 137.6, 134.2, 131.8, 
130.8, 129.01, 128.84, 127.93, 127.90, 127.6, 126.9, 122.7, 117.5, 117.0, 48.1, 45.1, 37.2. 
5-(7-Chloro-2-(phenethylamino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-
thioxo-3,4-dihydropyrimidin-2(1H)-one (10). Following General Procedure 2, 48 (35 mg, 0.071 
mmol) was converted to the title compound 10 at 2% MeOH/DCM as a yellow solid (21 mg, 0.043 
mmol, 60%). LC-MS (ESI+) Rt: 3.03 min (254 nm, Method 1); (m/z): 492.8 [M(35Cl)+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ: 12.67 (s, 1H), 8.04 (t, J = 5.4 Hz, 1H), 7.64 (s, 1H), 7.57 (d, J = 
8.6 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.35 (dd, J = 8.4, 2.3 Hz, 1H), 7.32-7.24 (m, 4H), 7.22-7.18 
(m, 1H), 6.87 (s, 2H), 5.72 (s, 1H), 3.52-3.45 (m, 2H), 3.27 (s, 3H), 2.87 (t, J = 7.3 Hz, 2H). 13C 
NMR (101 MHz, DMSO-d6) δ: 189.2, 169.3, 148.5, 143.5, 142.4, 139.7, 137.6, 134.1, 131.9, 
130.8, 129.14, 129.01, 128.8, 127.9, 126.73, 126.61, 122.7, 117.6, 116.6, 46.1, 45.2, 37.2, 35.1. 
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5-(7-Chloro-2-(4-methylpiperazin-1-yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one (11). Following General Procedure 2, 49 (47 
mg, 0.103 mmol) was converted to the title compound 11 which was isolated at 5% MeOH/DCM 
w.0.1% 880 NH3, as a yellow solid (4.5 mg, 0.0095 mmol, 9%).  LC-MS (ESI+) Rt: 2.28 min (254 
nm, Method 1); (m/z): 472.1 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.67 (s, 1H), 7.61 
(d, J = 8.5 Hz, 1H), 7.54 (s, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.36 (dd, J = 8.4, 2.4 Hz, 1H), 6.94 (d, 
J = 11.6 Hz, 1H), 6.91 (d, J = 11.7 Hz, 1H), 5.79 (s, 1H), 3.46-3.41 (m, 4H), 3.28 (s, 3H), 2.47-
2.42 (m, 4H), 2.27 (s, 3H).  
5-(7-Chloro-2-morpholino-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-
thioxo-3,4-dihydropyrimidin-2(1H)-one (12). Following General Procedure 2, 50 (44 mg, 0.100 
mmol) was converted to the title compound 12 which was isolated at 2% MeOH/DCM, a yellow 
solid (20 mg, 0.044 mmol, 44%). LC-MS (ESI+) Rt: 2.94 min (254 nm, Method 1); (m/z): 459.2 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (s, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.56 (s, 
1H), 7.46 (d, J = 2.3 Hz, 1H), 7.35 (dd, J = 8.4, 2.3 Hz, 1H), 6.95 (d, J = 11.6 Hz, 1H), 6.91 (d, J 
= 11.7 Hz, 1H), 5.77 (s, 1H), 3.69 (t, J = 4.9 Hz, 4H), 3.39 (t, J = 4.8 Hz, 4H), 3.28 (s, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ: 189.2, 171.3, 149.2, 148.5, 143.3, 137.4, 134.1, 132.2, 131.0, 
129.2, 128.0, 127.6, 122.4, 118.5, 117.3, 65.8, 48.3, 45.4, 37.2. 
5-(7-Chloro-2-(piperidin-1-yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-
thioxo-3,4-dihydropyrimidin-2(1H)-one (13). Following General Procedure 2, 51 (44 mg, 0.100 
mmol) was converted to the title compound 13 which was isolated at 2% MeOH/DCM as a yellow 
solid (34 mg, 0.074 mmol, 74%). LC-MS (ESI+) Rt: 3.14 min (254 nm, Method 1); (m/z): 456.8 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.65 (s, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.51 (s, 
1H), 7.44 (d, J = 2.3 Hz, 1H), 7.34 (dd, J = 8.4, 2.3 Hz, 1H), 6.90 (d, J = 11.6 Hz, 1H), 6.87 (d, J 
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= 11.7 Hz, 1H), 5.76 (s, 1H), 3.40 (s, 4H), 3.27 (s, 3H), 1.57 (s, 6H). 13C NMR (101 MHz, DMSO-
d6) δ: 189.2, 171.0, 149.5, 148.5, 143.1, 137.4, 133.9, 132.4, 130.9, 129.2, 127.9, 127.0, 122.4, 
117.8, 117.3, 49.2, 45.5, 37.2, 25.1, 23.9. 
5-(7-Chloro-2-((2-methoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one (14). Following General Procedure 2, 52 (40 
mg, 0.093 mmol) was converted to the title compound 14 at 2% MeOH/DCM a yellow solid (14 
mg, 0.031 mmol, 34%). LC-MS (ESI+) Rt: 2.74 min (254 nm, Method 1); (m/z): 446.9 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.65 (s, 1H), 8.00 (t, J = 5.4 Hz, 1H), 7.63 (s, 
1H), 7.55 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.33 (dd, J = 8.4, 2.3 Hz, 1H), 6.86 (s, 
2H,), 5.68 (s, 1H), 3.49-3.46 (m, 2H), 3.43-3.39 (m, 2H), 3.28 (s, 3H), 3.26 (s, 3H). 13C NMR (101 
MHz, DMSO-d6) δ: 189.2, 169.4, 148.8, 148.5, 143.5, 137.6, 134.1, 130.8, 129.0, 127.8, 126.8, 
122.7, 117.4, 116.7, 70.6, 58.4, 45.2, 44.2, 37.2.  
The two enantiomers were isolated by Chiral-HPLC: 20 (Rt: 34.46 min; 99% ee) and 21 (Rt: 
43.43 min; 78% ee).  
5-(7-Chloro-2-((3-methoxypropyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one (15). Following General Procedure 2, 53 (36 
mg, 0.080 mmol) was converted to the title compound 15 which was isolated at 2% MeOH/DCM, 
a yellow solid (35 mg, 0.076 mmol, 95%). LC-MS (ESI+) Rt: 2.75 min (254 nm, Method 1); (m/z): 
461.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (s, 1H), 7.94 (t, J = 5.5 Hz, 1H), 
7.65 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.35 (dd, J = 8.4, 2.3 Hz, 1H), 
6.87 (s, 2H), 5.70 (s, 1H), 3.38 (t, J = 6.2 Hz, 2H), 3.30 (s, 3H), 3.28-3.24 (m, 2H), 3.23 (s, 3H), 
1.78 (app.qi, J = 6.6 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ: 189.2, 169.5, 149.0, 148.5, 
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143.4, 137.6, 134.1, 130.8, 129.0, 127.8, 126.7, 122.7, 117.5, 116.5, 110.0, 69.8, 58.4, 45.2, 41.9, 
37.2, 29.2. 
5-(7-Chloro-2-((2-ethoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one (16). Following General Procedure 2, 54 (36 
mg, 0.080 mmol) was converted to the title compound 16 which was isolated at 2% MeOH/DCM, 
a yellow solid (34 mg, 0.074 mmol, 92%). LC-MS (ESI+) Rt: 2.81 min (254 nm, Method 1); (m/z): 
461.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (s, 1H), 8.00 (t, J = 5.5 Hz, 1H), 
7.64 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.35 (dd, J = 8.4, 2.3 Hz, 1H), 
6.87 (s, 2H), 5.70 (s, 1H), 3.53-3.50 (m, 2H), 3.45 (q, J = 7.0 Hz, 2H), 3.43-3.38 (m, 2H), 3.30 (s, 
3H), 1.11 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 189.3, 169.4, 148.8, 148.5, 143.5, 
137.6, 134.1, 132.0, 130.8, 129.0, 127.8, 126.7, 122.7, 117.5, 116.7, 68.5, 65.9, 45.2, 44.5, 37.2, 
15.6. 
The two enantiomers were isolated by Chiral-HPLC: 22 (Rt: 28.32 min; 95% ee) and 23 (Rt: 
36.68 min; 96% ee). 
5-(7-Chloro-2-((2-isopropoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one (17). Following General Procedure 2, 55 (37 
mg, 0.080 mmol) was converted to the title compound 17 which was isolated at 2% MeOH/DCM, 
a yellow solid (30 mg, 0.063 mmol, 79%). LC-MS (ESI+) Rt: 2.88 min (254 nm, Method 1); (m/z): 
475.1 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (s, 1H), 7.97 (t, J = 5.4 Hz, 1H), 
7.63 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.35 (dd, J = 8.4, 2.3 Hz, 1H), 
6.87 (s, 2H), 5.70 (s, 1H), 3.57 (sep., J = 6.1 Hz, 1H), 3.52-3.49 (m, 2H), 3.39-3.37 (m, 2H), 3.30 
(s, 3H), 1.08 (d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, DMSO-d6) δ: 189.2, 169.4, 148.5, 143.5, 
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137.6, 134.1, 132.0, 130.8, 129.0, 127.9, 126.7, 122.7, 117.5, 116.7, 71.3, 66.0, 45.2, 44.9, 37.2, 
22.51, 22.48. 
5-(7-Chloro-2-((2-phenoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methyl-4-thioxo-3,4-dihydropyrimidin-2(1H)-one (18). Following General Procedure 2, 56 (39 
mg, 0.080 mmol) was converted to the title compound 18. This was isolated at 2% MeOH/DCM 
and further purification was achieved by preparative RP-HPLC (Method 3) isolating the title 
compound 18 at Rt: 18.57 min which was freeze dried to an orange solid (8 mg, 0.016 mmol, 
20%). LC-MS (ESI+) Rt: 3.02 min (254 nm, Method 1); (m/z): 509.0 [M(35Cl)+H]+. 1H NMR (400 
MHz, DMSO-d6) δ: 12.66 (s, 1H), 8.20 (t, J = 5.3 Hz, 1H), 7.63 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 
7.45 (d, J = 2.2 Hz, 1H), 7.35 (dd, J = 8.4, 2.3 Hz, 1H), 7.29 (app.t, J = 8.0 Hz, 2H), 6.97-6.92 
(m, 3H), 6.88 (s, 2H), 5.72 (s, 1H), 4.13 (t, J = 5.4 Hz, 2H), 3.64 (app.q, J = 5.4 Hz, 2H), 3.27 (s, 
3H).  
5-(7-Chloro-2-phenyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methyl-4-thioxo-3,4-
dihydropyrimidin-2(1H)-one (19). Following General Procedure 2, 44 (15 mg, 0.035 mmol) was 
converted to the title compound 19 which was purified by FC (20-50% ethyl acetate/petroleum 
ether)  and isolated at 50% ethyl acetate/petroleum ether, a yellow solid (12 mg, 0.027 mmol, 
76%). LC-MS (ESI+) Rt: 3.20 min (254 nm, Method 1); (m/z): 450.1 [M(35Cl)+H]+. LC-MS 
(ESI+) Rt: 6.99 min (254 nm, Method 2); (m/z): 450.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-
d6) δ: 12.76 (s, 1H), 7.96-7.94 (m, 2H), 7.88 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 2.1 Hz, 
1H), 7.53-7.49 (m, 3H), 7.45 (dd, J = 8.4, 2.2 Hz, 1H), 7.27 (d, J = 11.6 Hz, 1H), 7.22 (d, J = 11.8 
Hz, 1H), 6.04 (s, 1H), 3.37 (s, 3H).. 13C NMR (101 MHz, DMSO-d6) δ: 189.3, 167.2, 152.5, 148.5, 
144.1, 137.0, 135.4, 133.2, 131.60, 131.50, 131.36, 131.1, 129.90, 129.79, 129.61, 129.0, 126.5, 
122.0, 117.2, 45.0, 37.2. 
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2-((5-(7-Chloro-2-((2-methoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-
2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-
carboxamide (24). A stirred solution of 59 (140mg, 0.23 mmol) in MeOH (10 mL) was treated 
with 2M NaOH (0.35 mL, 0.69 mmol) and heated to reflux for 1 h. under N2. Completion was 
observed by TLC and the crude evaporated directly onto silica and purified by FC, washing with 
5% MeOH/DCM before eluting off the desired compound with 20% MeOH/DCM w. 1% acetic 
acid to afford a yellow solid. This was dissolved in EA (20 mL), washed with 1M HCl (10 mL),  
brine (10mL), dried over MgSO4, filtered and concentrated in vacuo to afford the corresponding 
carboxylic acid as an orange solid (120 mg, 0.20 mmol, 91%). LC-MS (ESI+) Rt: 2.68 min (254 
nm, Method 1); (m/z): 573.9 [M(35Cl)+H]+. The acid (20 mg, 0.035 mmol) in DMF (1.5 mL) was 
treated with DIPEA (50 μL) and 5-aminotetrazole monohydrate (22 mg, 0.203 mmol) followed by 
PyBroP (24 mg, 0.051 mmol) and stirred at RT for 2 h. until completion was observed by LC-MS. 
The RM was quenched with water (c.a. 2 drops), diluted with EA (20 mL), partitioned with 1M 
HCl (10mL) and the organics extracted with EA (2 x 10 mL), combined washed with brine (10mL), 
dried over MgSO4, filtered and concentrated in vacuo azeotroping DMF with toluene (3 x 50 mL) 
to afford an orange oil. This was purified by washing with 10% MeOH/DCM before eluting off 
the desired compound with 10% MeOH/DCM w. 1% acetic acid affording the title compound. 
Further purification was achieved by preparative RP-HPLC (Method 3) isolating the title 
compound 24 at Rt: 7.37 min which was freeze dried to an orange solid (8 mg, 0.016 mmol, 
34%).LC-MS (ESI+) Rt: 2.71 min (254 nm, Method 1); (m/z): 640.9 [M(35Cl)+H]+. LC-MS (ESI+) 
Rt: 5.12 min (254 nm, Method 2); (m/z): 640.9 [M(35Cl)+H]+. H.MS-TOF (ESI-) (m/z): [M-H]- 
calcd. for C25H20ClN10O3S3, 639.0576; found, 639.0569. 
1H NMR (400 MHz, DMSO-d6) δ: 12.89 
(s, 1H), 12.30-12.23 (m, 1H), 8.74 (s, 1H), 7.98 (t, J = 4.9 Hz, 1H), 7.76 (s, 1H), 7.57 (d, J = 8.5 
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Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.34 (dd, J = 8.4, 2.3 Hz, 1H), 6.76 (s, 2H), 5.67 (s, 1H), 5.45 
(d, J = 16.0 Hz, 1H), 5.30 (d, J = 16.0 Hz, 1H), 3.42-3.33 (m, 4H), 3.22 (s, 3H). 13C NMR (126 
MHz, DMSO-d6) δ: 189.8, 176.9, 169.4, 165.9, 159.4, 148.0, 141.9, 137.5, 133.7, 131.2, 130.8, 
129.44, 129.35, 128.9, 128.7, 127.8, 126.7, 122.6, 117.7, 116.7, 70.6, 58.3, 49.4, 46.3, 44.1. 
3-(3-Chlorophenyl)propanal (26). A stirred solution of 3-chloroiodobenzene (50.00 g, 210 
mmol), allyl alcohol (21.4 mL, 18.27 g, 314 mmol), tetrabutylammonium chloride (58.26 g, 210 
mmol) and NaHCO3 (17.61 g, 210 mmol) dissolved in anhydrous DMF (150 mL) cooled in an ice 
bath under N2 was treated portion-wise with Pd(OAc)2 (1.40 g, 6.29 mmol) over 30 min. This was 
then heated to 50oC for 18 h. and consumption of the 3-chloroiodobenzene was observed by TLC 
(15% ethyl acetate/petroleum ether). The reaction was concentrated in vacuo, azeotroping the 
DMF with toluene (3 x 200 mL). The resulting black gum was dissolved in Et2O (300 mL) and 
water (300 mL), filtered, the organics were extracted with Et2O (2 x 300 mL), combined, washed 
with brine (100 mL), dried over MgSO4 and concentrated in vacuo to afford a black oil. Further 
purification was achieved by FC (10-40% Et2O/PE) affording the title compound 27 (32.30 g, 192 
mmol, 92%). LC-MS (ESI+) Rt: 2.72 min (254 nm, Method 1); (m/z): not observed. 1H NMR (400 
MHz, CDCl3) δ: 9.81 (t, J = 1.2 Hz, 1H), 7.22-7.17 (m, 3H), 7.07 (dt, J = 7.1, 1.6 Hz, 1H), 2.93 
(t, J = 7.4 Hz, 2H), 2.80-2.76 (m, 2H).  13C NMR (101 MHz, CDCl3) δ: 200.9, 142.5, 134.3, 129.9, 
128.5, 126.6, 126.51, 44.9, 27.7.  
Ethyl 5-(3-chlorophenethyl)-2-methylthiazole-4-carboxylate (27). A stirred solution of 26 
(24.00 g, 143 mmol) and ethyl dichloroacetate (22.42 g, 143 mmol) dissolved in anhydrous diethyl 
ether (120 mL) cooled to below -10oC in an ice/salt bath, under N2, was treated with a freshly 
prepared solution of sodium ethoxide (2.2 M, 50 mL, 110 mmol) over a 15 min period ensuring 
the temperature did not raise above 0oC; generating a pale orange suspension. This was stirred for 
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45 min and then warmed to 40oC over 30 min. This was then quenched with water (250 mL) and 
the organics extracted with diethyl ether (3 x 150 mL). These were combined, washed with brine 
(100 mL), dried over MgSO4, filtered and concentrated in vacuo to afford to afford an orange oil. 
This was dissolved in ethanol (80 mL) and added dropwise to a warm solution of thioacetamide 
(16.09 g, 214 mmol) in ethanol (80 mL) heated to 65oC over a 10 min period. This was heated to 
reflux for 3 h. generating a red solution with a white precipitate which was allowed to cool to rt 
and concentrated in vacuo. The residue was then diluted with diethyl ether (200 mL), partitioned 
with NaHCO3 (100 mL) and water (100 mL). The organics where extracted with diethyl ether (3 
x 200 mL), combined, washed with brine (100 mL) dried over MgSO4, filtered and concentrated 
in vacuo to afford a brown oil. This was purified by FC (10-30% ethyl acetate/petroleum ether) to 
afford the title compound 27 at 15% ethyl acetate/petroleum ether, a yellow solid (13.21 g, 42.7 
mmol, 30%). LC-MS (ESI+) Rt: 3.04 min (254 nm, Method 1); (m/z): 310.0 [M(35Cl)+H]+ 1H 
NMR (400 MHz, CDCl3) δ: 7.21-7.19 (m, 3H), 7.08-7.06 (m, 1H), 4.42 (q, J = 7.1 Hz, 2H), 3.48 
(t, J = 7.8 Hz, 2H), 2.95 (t, J = 7.8 Hz, 2H), 2.67 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ: 162.5, 162.2, 148.4, 142.3, 140.6, 134.2, 129.7, 128.6, 126.73, 126.59, 61.2, 37.0, 
28.8, 19.3, 14.5. 
5-(3-Chlorophenethyl)-2-methylthiazole-4-carboxylic acid (28). A stirred solution of 27 
(13.00 g, 42.0 mmol) in THF (60 mL) was treated with a solution of NaOH (2.52g, 63.0 mmol) in 
water (60 mL) this was stirred for 24 h. at rt. This was treated with 2M HCl (100 mL) and the 
organics extracted with ethyl acetate (3 x100 mL), combined, washed with brine (100 mL), dried 
over MgSO4, filtered and concentrated in vacuo to afford the title compound 28, a pale yellow 
solid (11.68 g, 41.4 mmol, 99%). 1H NMR (400 MHz, CDCl3) δ: 9.38-9.07 (br.s, 1H), 7.25-7.19 
(m, 3H), 7.10 (dt, J = 6.5, 1.9 Hz, 1H), 3.52 (t, J = 7.8 Hz, 2H), 2.98 (t, J = 7.8 Hz, 2H), 2.69 (s, 
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3H). 13C NMR (101 MHz, CDCl3) δ: 163.2, 149.6, 142.0, 139.6, 134.3, 129.8, 128.7, 126.8, 126.7, 
36.8, 28.8, 18.9. 
7-Chloro-2-methyl-9,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-one (29). A 
stirred solution of 28 (11.27 g, 40 mmol) in DCM (120 mL) under N2 was treated with oxalyl 
chloride (6.00 mL, 70 mmol) and catalytic DMF (c.a. 2 drops) and stirred for 3 h. at rt. This was 
then concentrated in vacuo azeotroping residual oxalyl chloride with toluene (3 x 50 mL) to afford 
an orange solid. This was dissolved in DCM (175 mL), cooled in an ice bath under N2 and treated 
portion-wise with aluminium(III)chloride (21.33 g, 160 mmol) generating a black solution. This 
was allowed to warm to rt and stirred for 18 h. This was gradually added to a stirred slurry of ice 
and 2M HCl (400 mL) and allowed to warm to rt. The organics were extracted with ethyl acetate 
(3 x 400 mL), combined, washed with brine (300 mL), dried over MgSO4, filtered and concentrated 
in vacuo to afford a crude solid. This was purified by FC (20-100% ethyl acetate/petroleum ether) 
to afford the title compound 29 at 50% ethyl acetate/petroleum ether, a beige solid (4.16 g, 15.6 
mmol, 39%). LC-MS (ESI+) Rt: 2.70 min (254 nm, Method 1); (m/z): 264.1 [M(35Cl)+H]+ 1H 
NMR (400 MHz, CDCl3) δ: 7.77 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.48 (dd, J = 8.4, 
2.2 Hz, 1H), 3.28-3.25 (m, 2H), 3.21-3.18 (m, 2H), 2.63 (s, 3H). 
5-Bromo-2,4-di-tert-butoxypyrimidine (31).  To a stirred solution of 5-bromo-2,4-
dichloropyrimidine (5.00 g, 22.00 mmol) in anhydrous THF (70 mL) cooled in an ice bath under 
N2, a suspension of sodium tert-butoxide (6.35 g, 66.0 mmol) in anhydrous THF (50 mL) was 
added dropwise via a dropping funnel over a 30 min period. This was allowed to warm to rt and 
stirred for a further 18 h. generating a dark brown solution. The RM was then quenched with  aq. 
NH4Cl (10 mL), diluted with water (100 mL), the organics extracted with ethyl acetate (3 x 75 
mL), combined, washed with brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo 
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to afford a black oil. Further purification was achieved by FC (2.5% diethyl ether/petroleum ether 
w. 0.1% Et3N) to afford the title compound 31 a clear oil that crystallized to a white solid on 
standing (4.08 g, 13.50 mmol, 61%). LC-MS (ESI+) Rt: 3.32 min (254 nm, Method 1); (m/z): 
305.2 [M(81Br)+H]+, 303.2 [M(79Br)+H]+. 1H NMR (400 MHz, CDCl3) δ: 8.24 (s, 1H), 1.64 (s, 
9H), 1.59 (s, 9H). 13C NMR (101 MHz, CDCl3) δ: 165.7, 163.0, 159.0, 99.6, 83.3, 80.8, 28.3, 28.3. 
7-Chloro-4-(2,4-di-tert-butoxypyrimidin-5-yl)-2-methyl-9,10-dihydro-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-4-ol (32). A stirred solution of 31 (3.03 g, 10.00 mmol) in 
unstabilized, anhydrous THF (80 mL) under N2 was cooled to -78
oC and treated dropwise with a 
solution of n-butyllithium (2.46 M in hexane, 4.1 mL, 10.50 mmol) and stirred for 30 min 
generating a dark orange solution. This was then treated dropwise with a solution of 29 (2.64 g, 
10.00 mmol) dissolved in unstabilized, anhydrous THF (20 mL) and stirred at -78oC for 15 min, 
allowed to warm to rt and stirred for 1 h. The RM was then quenched with NH4Cl (50 mL), diluted 
with water (50 mL) and the organics extracted with ethyl acetate (3 x 100 mL). These were 
combined, washed with brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to 
afford an orange oil. Further purification was achieved by FC (5-20% ethyl acetate/petroleum 
ether) affording the title compound 32 at 15% ethyl acetate/petroleum ether, a clear oil that foamed 
and crystallized to a white solid under high vacuum (3.04 g, 6.23 mmol, 65%). LC-MS (ESI+) Rt: 
3.36 min (254 nm, Method 1); (m/z): 488.2 [M(35Cl)+H]+.  1H NMR (400 MHz, DMSO-d6) δ: 7.88 
(s, 1H), 7.38 (d, J = 8.5 Hz, 1H), 7.33 (d, J = 2.3 Hz, 1H), 7.24 (dd, J = 8.5, 2.4 Hz, 1H), 6.13 (s, 
1H), 3.25-3.18 (m, 1H), 2.97-2.94 (m, 2H), 2.87-2.80 (m, 1H), 2.53 (s, 3H), 1.56 (s, 9H), 1.18 (s, 
9H). 13C NMR (101 MHz, DMSO-d6) δ: - 167.0, 163.2, 160.2, 156.1, 151.7, 143.3, 141.4, 131.84, 
131.67, 129.37, 129.24, 125.8, 122.1, 81.2, 80.0, 75.3, 31.8, 28.6, 28.1, 26.9, 19.0. 
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5-(7-Chloro-2-methyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)pyrimidine-2,4(1H,3H)-
dione (33). A stirred solution of 32 (1.54 mmol, 0.750 g) in trifluoroacetic acid (20 mL) was heated 
to reflux under N2 for 72 h. generating a black solution. This concentrated in vacuo to give dark 
red gum which was trituration with Et2O (3 x 10 mL) to give orange solid (454 mg) which was 
purified by FC (2-10% MeOH/DCM w. 0.1% 880 NH3) affording the title compound 33 at 4% 
MeOH/DCM w. 0.1% 880 NH3, a pink solid (200 mg, 0.56 mmol, 36%). LC-MS (ESI+) Rt: 2.80 
min (254 nm, Method 1); (m/z): 358.1 [M(35Cl)+H]+.  1H NMR (400 MHz, DMSO-d6) δ: 11.07 (s, 
1H), 10.57 (d, J = 6.1 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.45 (dd, J = 
8.3, 2.3 Hz, 1H), 7.08 (d, J = 11.7 Hz, 1H), 7.01 (d, J = 11.7 Hz, 1H), 6.66 (d, J = 5.5 Hz, 1H), 
5.50 (s, 1H), 2.64 (s, 3H). 
5-(7-Chloro-2-methyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methylpyrimidine-
2,4(1H,3H)-dione (34). A stirred suspension of 33 (100 mg, 0.28 mmol) in DCM (15 mL) under 
N2 was treated with N,O-bis(trimethylsilyl)trifluoroacetamide (0.3 mL, 287 mg, 1.18 mmol) and 
heated to reflux for 18 h. This was cooled, treated with iodomethane (1.5 mL) and heated to 50oC 
for 24 h. until completion was observed by LC-MS. This was concentrated in vacuo affording an 
oil which was dissolved in MeOH and re-concentrated in vacuo to afford as a solid. This was 
purified by FC (1-4% MeOH/DCM w. 0.1% 880 NH3) to afford the title compound 34 at 2% 
MeOH/DCM w. 0.1% 880 NH3 (64 mg, 0.17 mmol, 61%). LC-MS (ESI+) Rt: 2.64 min (254 nm, 
Method 1); (m/z): 372.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 11.26 (s, 1H), 7.53 (d, 
J = 8.4 Hz, 1H), 7.51 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 8.3, 2.3 Hz, 1H), 7.07 (d, J = 11.7 Hz, 
1H), 7.01 (d, J = 11.7 Hz, 1H), 6.90 (s, 1H), 5.52 (s, 1H), 3.15 (s, 3H), 2.65 (s, 3H). 
Ethyl 2-((5-(7-chloro-2-methyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)thiazole-4-carboxylate (35). A stirred suspension of 33 
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(160 mg, 0.28 mmol) in 1,2-dichloroethane (10 mL) was treated with N,O-
bis(trimethylsilyl)trifluoroacetamide (0.3 mL, 1.18 mmol) and heated to reflux for 18 h. under N2. 
This was then treated with ethyl 5-(bromomethyl)thiophene-3-carboxylate (104 mg, 0.42mmol) 
dissolved in 1,2-dichloroethane (5 mL) and refluxed for 48 h. This was concentrated in vacuo to a 
gum, treated with MeOH (20 mL) and then re-concentrated in vacuo to a solid. This was purified 
by chromatography on silica gel (1-5% MeOH/DCM) affording the title compound 35 at 3% 
MeOH/DCM (84 mg, 0.16 mmol, 57%). LC-MS (ESI+) Rt: 2.82 min (254 nm, Method 1); (m/z): 
526.9 [M(35Cl)+H]+ 1H NMR (400 MHz, CDCl3) δ: 8.28-8.25 (br.s, 1H), 8.22 (s, 1H), 7.56 (d, J 
= 8.3 Hz, 1H), 7.38 (dd, J = 8.3, 2.2 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 6.87 (s, 1H), 6.84 (d, J = 
11.6 Hz, 1H), 6.75 (d, J = 11.7 Hz, 1H), 5.79 (s, 1H), 5.21 (d, J = 15.2 Hz, 1H), 4.98 (d, J = 15.2 
Hz, 1H), 4.51 (q, J = 7.1 Hz, 2H), 2.71 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H). 
Ethyl 2-((5-(7-chloro-2-methyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-
thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)thiazole-4-carboxylate (36). Following 
General Procedure 2, 35 (80 mg, 0.151 mmol) was converted to the title compound 36 at 2% 
MeOH/DCM, a yellow solid (68 mg, 0.125 mmol, 89%). LC-MS (ESI+) Rt: 3.01 min (254 nm, 
Method 1); (m/z): 542.8 [M(35Cl)+H]+ 1H NMR (400 MHz, CDCl3) δ: 9.63 (s, 1H), 8.24 (s, 1H), 
7.69 (d, J = 8.3 Hz, 1H), 7.36 (dd, J = 8.3, 2.1 Hz), 7.29 (d, J = 2.2 Hz, 1H), 7.25 (s, 1H), 6.91 (d, 
J = 11.6 Hz, 1H), 6.84 (d, J = 11.5 Hz, 1H), 6.20 (s, 1H), 5.26 (d, J = 15.1 Hz, 1H), 5.03 (d, J = 
15.0 Hz, 1H), 4.52 (q, J = 7.1 Hz, 2H), 2.71 (s, 3H), 1.49 (t, J = 7.1 Hz, 3H). 
Ethyl 2-amino-5-(3-chlorophenethyl)thiazole-4-carboxylate (37). A stirred solution of 26 
(18.50 g, 110 mmol) and ethyl dichloroacetate (17.29 g, 110 mmol), dissolved in anhydrous diethyl 
ether (90 mL) cooled to below -10oC in an ice/salt bath under N2, was treated with a freshly 
prepared solution of sodium ethoxide (2.2M, 50 mL, 110 mmol) over a 15 min period ensuring the 
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temperature did not raise above 0oC generating a pale orange suspension. This was stirred for 45 
min and warmed to 40oC over 30 min. This was then quenched with water (250 mL) and the 
organics extracted with diethyl ether (3 x 150 mL). These were combined, washed with brine (100 
mL), dried over MgSO4, filtered and concentrated in vacuo to afford to afford an orange oil. This 
was dissolved in ethanol (60 mL) and added dropwise to a warm solution of thiourea (12.56 g, 165 
mmol) in ethanol (60 mL) heated to 65oC over a 10 min period. This was heated to reflux for 2.5 
h. generating a purple/red solution and white precipitate which was then allowed to cool to rt, and 
concentrated in vacuo. The residue was then diluted with diethyl ether (200 mL), partitioned with 
NaHCO3 (100 mL) and water (100 mL). The organics where extracted with diethyl ether (3 x 200 
mL), combined, washed with brine (100 mL) dried over MgSO4, filtered and concentrated in vacuo 
to afford a brown oil. This was taken up in a diethyl ether (100 mL) and filtered th.ough a plug of 
silica washing with diethyl ether (3 x 200 mL). The filtrate was concentrated to afford an orange 
solid which was triturated with diethyl ether/hexane to give the title compound 37 a yellow solid 
(15.70 g, 50.5 mmol, 46%).  LC-MS (ESI+) Rt: 2.81 min (254 nm, Method 1); (m/z): 311.3 
[M(35Cl)+H]+.  1H NMR (400 MHz, CDCl3) δ: 7.21-7.19 (m, 3H), 7.09-7.07 (m, 1H), 5.09 (s, 2H), 
4.36 (q, J = 7.1 Hz, 2H), 3.37 (t, J = 7.8 Hz, 2H), 2.91 (t, J = 7.8 Hz, 2H), 1.39 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ: 163.4, 162.3, 142.6, 139.5, 136.9, 134.3, 129.8, 128.8, 126.9, 
126.6, 61.1, 37.1, 28.8, 14.6. 
Ethyl 2-chloro-5-(3-chlorophenethyl)thiazole-4-carboxylate (38).  A stirred solution of 37 
(15.00 g, 48.26 mmol) in degassed, anhydrous acetonitrile (240 mL) under N2 was treated with 
copper(II)chloride (12.92 g, 96.25 mmol) and then treated dropwise, via a syringe pump, with tert-
butyl nitrite (11.50 mL, 96.25 mmol) over a 15 min period at rt ensuring the temperature did not 
rise above 25oC. This was stirred for a further 2 h. at rt, quenched with 2M HCl (250 mL), stirred 
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for 10 min and then the organics extracted with ethyl acetate (3 x 250mL). These were combined, 
washed with brine (200 mL), dried over MgSO4, filtered and concentrated in vacuo to afford an 
orange oil. Further purification was achieved by FC (10% ethyl acetate/petroleum ether) to afford 
the title compound 38, an orange oil (10.41 g. 31.53 mmol, 65%). LC-MS (ESI+) Rt: 3.18 min 
(254 nm, Method 1); (m/z): 330.0 [M(35Cl)+H]+. 1H NMR (400 MHz, CDCl3) δ: 7.21-7.18 (m, 
3H), 7.05 (dt, J = 6.0, 2.1 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.48 (t, J = 7.7 Hz, 2H), 2.95 (t, J = 
7.7 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 161.2, 150.5, 148.3, 141.7, 
139.8, 134.4, 129.9, 128.6, 126.9, 126.7, 61.6, 36.6, 28.9, 14.4. 
2-Chloro-5-(3-chlorophenethyl)thiazole-4-carboxylic acid (39). A stirred solution of 38 
(10.00 g, 30.3 mmol) in THF (40 mL) was treated with a solution of NaOH (1.817 g, 45.4 mmol) 
in water (40 mL) this was stirred for 24 h. at rt. This was treated with 2M HCl (100 mL) and the 
organics extracted with ethyl acetate (3 x 100 mL), combined, washed with brine (50 mL), dried 
over MgSO4, filtered and concentrated in vacuo to afford the title compound 39 as a pale yellow 
solid (9.15 g, 30.3 mmol, 100%.). LC-MS (ESI+) Rt: 2.88 min (254 nm, Method 1); (m/z): 301.9 
[M(35Cl)+H]+. 1H NMR (400 MHz, CDCl3) δ: 7.24-7.20 (m, 3H), 7.09-7.06 (m, 1H), 3.53 (t, J = 
7.7 Hz, 2H), 2.98 (t, J = 7.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ: 162.4, 151.9, 148.6, 141.4, 
138.8, 134.5, 130.0, 128.7, 127.0, 126.7, 36.4, 28.9. 
2,7-Dichloro-9,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-one (40). A stirred 
solution of 39 (7.00 g, 23.17 mmol) in DCM (70 mL) under N2 was treated with oxalyl chloride 
(3.47 mL, 40.54 mmol) and catalytic DMF (c.a. 2 drops) and stirred for 3 h. at rt. This was then 
concentrated in vacuo azeotroping residual oxalyl chloride with toluene (3 x 50 mL) to afford an 
orange solid. The solid was dissolved in DCM (100 mL), cooled in an ice bath under N2 and treated 
portionwise with aluminium(III)chloride (12.36 g, 92.68 mmol) generating a black solution. This 
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was allowed to warm to rt and stirred for 18 h. This was gradually added to a stirred slurry of ice 
and 2M HCl (250 mL) and allowed to warm to rt. The organics were extracted with ethyl acetate 
(3 x 200 mL), combined, washed with brine (100 mL), dried over MgSO4, filtered and concentrated 
in vacuo to afford and orange solid. This was triturated with diethyl ether/hexane to afford the title 
compound 40, a beige solid (5.48 g, 19.28 mmol, 83%). LC-MS (ESI+) Rt: 2.88 min (254 nm, 
Method 1); (m/z): 284.0 [M(35Cl)+H]+.  1H NMR (400 MHz, DMSO-d6) δ: 7.78 (d, J = 8.4 Hz, 
1H), 7.55 (d, J = 2.1 Hz, 1H), 7.48 (dd, J = 8.4, 2.2 Hz, 1H), 3.29-3.26 (m, 2H), 3.24-3.21 (m, 
2H). 13C NMR (101 MHz, DMSO-d6) δ: 183.5, 153.2, 148.6, 147.9, 142.1, 137.7, 137.0, 132.6, 
129.9, 127.7, 33.5, 26.7. 
2,7-Dichloro-4-(2,4-di-tert-butoxypyrimidin-5-yl)-9,10-dihydro-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-4-ol (41). A stirred solution of 31 (1.516 g, 5.00 mmol) in 
unstabilized, anhydrous THF (40 mL) under N2 was cooled to -78
oC and treated dropwise with a 
solution of n-butyllithium (2.25M in hexane, 2.33 mL, 5.25 mmol) and stirred for 30 min 
generating a dark orange solution. This was then treated dropwise with a solution of 82 (1.421 g, 
5.00 mmol) dissolved in unstabilized, anhydrous THF (10 mL) and stirred at -78oC for 15 min, 
allowed to warm to rt and stirred for 1 h. The RM was then quenched with aq. NH4Cl (20 mL), 
diluted with water (20 mL) and the organics extracted with ethyl acetate (3 x 50 mL). These were 
combined, washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo to 
afford an orange oil. Further purification was achieved by FC (5-20% ethyl acetate/petroleum 
ether) affording the title compound 41 at 15% ethyl acetate/petroleum ether a clear oil that foamed 
and crystallized to a white solid under high vacuum (2.00 g, 3.93 mmol, 79%). LC-MS (ESI+) Rt: 
3.46 min (254 nm, Method 1); (m/z): 508.3 [M(35Cl)+H]+. 1H NMR (400 MHz, CDCl3) δ: 8.02 (d, 
J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.31 (dd, J = 8.5, 2.3 Hz), 7.16 (d, J = 2.2 Hz, 1H), 5.16 (s, 1H), 
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3.12-3.04 (m, 2H), 2.87-2.77 (m, 1H), 2.72-2.66 (m, 1H), 1.61 (s, 9H), 1.43 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ: 167.1, 163.5, 156.9, 150.8, 147.1, 142.6, 137.9, 133.11, 133.07, 129.9, 
128.2, 126.5, 120.1, 82.5, 80.4, 74.4, 31.2, 28.42, 28.40, 26.7. 
5-(2,7-Dichloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)pyrimidine-2,4(1H,3H)-dione 
(42). A solution of 41 (1.990 g, 3.91 mmol) in 1,4-dioxane (19.5 mL) was treated with acetic acid 
(19.5 mL) and heated to 140OC with stirring in the MW for 10 min. This concentrated in vacuo 
azeotroping residual acetic acid with toluene (3 x 50 mL) to afford a brown solid. Purification was 
achieved by FC (5% MeOH/DCM) to afford the title compound 42, as an orange solid (851 mg, 
2.25 mmol, 58%). LC-MS (ESI+) Rt: 2.71 min (254 nm, Method 1); (m/z): 378.1 [M(35Cl)+H]+. 
1H NMR (400 MHz, DMSO-d6) δ: 11.08 (s, 1H), 10.60 (s, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.53 (d, 
J = 8.4 Hz, 1H), 7.49 (dd, J = 8.3, 2.2 Hz, 1H), 7.12 (d, J = 11.9 Hz, 1H) 7.07 (d, J = 11.7 Hz, 
1H), 6.63 (s, 1H), 5.48 (s, 1H). 13C NMR (101 MHz, DMSO-d6) δ: 163.4, 151.2, 150.6, 149.0, 
138.6, 136.2, 134.9, 133.1, 131.8, 131.5, 130.1, 129.8, 120.5, 108.3, 43.7. 
5-(2,7-Dichloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methylpyrimidine-
2,4(1H,3H)-dione (43). A stirred suspension of 42 (1.430 g, 3.80 mmol) in 1,2-dichloroethane (40 
mL) under N2 was treated with N,O-bis(trimethylsilyl)trifluoroacetamide (4.1 mL, 3.912g, 15.20 
mmol) and heated to reflux for 18 h. generating an orange solution. This was cooled, treated with 
iodomethane (4.7 mL, 10.737 g, 76.0 mmol) and heated to 500C for 6 h. until completion was 
observed by LC-MS. This was concentrated in vacuo affording an orange oil which was dissolved 
in MeOH and re-concentrated in vacuo to afford a yellow solid. This was triturated with diethyl 
ether (3 x 30 mL) to afford the title compound 43 an orange solid (1.466 g, 3.73 mmol, 98%). LC-
MS (ESI+) Rt: 2.83 min (254 nm, Method 1); (m/z): 392.0 [M(35Cl)+H]+. 1H NMR (400 MHz, 
DMSO-d6) δ: 11.27 (s, 1H), 7.56 (d, J = 2.3 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.48 (dd, J = 8.3, 
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2.2 Hz, 1H), 7.11 (d, J = 11.8 Hz, 1H), 7.05 (d, J = 11.7 Hz, 1H), 6.87 (d, J = 0.9 Hz, 1H), 5.50 
(s, 1H), 3.14 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 163.1, 151.1, 150.6, 148.8, 143.2, 136.2, 
134.8, 133.2, 132.1, 131.8, 131.5, 130.2, 129.7, 120.6, 108.4, 43.9, 36.0. 
5-(7-Chloro-2-phenyl-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methylpyrimidine-
2,4(1H,3H)-dione (44). A suspension of 43 (39 mg, 0.099 mmol), phenylboronic acid (15 mg, 
0.12 mmol), Na2CO3 (32 mg, 0.30 mmol), bis(triphenylphosphine) palladium(II)chloride (7 mg, 
0.01 mmol) in 1,4-dioxane (0.8 mL) and water (0.2 mL) were heated in a MW to 150OC for 5 min 
generating a black solution. This was concentrated directly onto silica a purified by FC (20-50% 
ethyl acetate/toluene) affording the title compound 44 at 30% ethyl acetate/toluene (29 mg, 0.067 
mmol, 68%). LC-MS (ESI+) Rt: 3.01 min (254 nm, Method 1); (m/z): 433.8 [M(35Cl)+H]+. LC-
MS (ESI+) Rt: 6.22 min (254 nm, Method 2); (m/z): 434.1 [M(35Cl)+H]+ (N.B. 85% purity at 
254nm; 95% purity at 220nm). 1H NMR (400 MHz, DMSO-d6) δ: 11.30 (s, 1H), 7.96-7.94 (m, 
2H), 7.61 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.53-7.49 (m, 3H), 7.48 (dd, J = 8.3, 2.3 
Hz, 1H), 7.19 (d, J = 11.7 Hz, 1H), 7.11 (d, J = 11.8 Hz, 1H), 7.06 (s, 1H), 5.62 (s, 1H), 3.18 (s, 
3H). 13C NMR (101 MHz, DMSO-d6) δ: 167.4, 163.2, 151.7, 151.1, 143.3, 136.4, 135.1, 133.2, 
131.6, 131.1, 130.8, 130.0, 129.8, 129.3, 126.47, 126.44, 121.4, 110.0, 108.8, 43.9, 36.1. 
5-(2-Amino-7-chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-methylpyrimidine-
2,4(1H,3H)-dione (45). A stirred solution of 43 (140 mg, 0.357 mmol) in 1,4-dioxane (1 mL) was 
treated with 880 NH3 (1 mL) and heated in a MW to 100
oC with stirring for 4 h. The RM was 
concentrated directly onto silica and purified by FC (5-20% MeOH DCM w.0.1% 880 NH3) 
affording the title compound 45 at 20% MeOH DCM w.0.1% 880 NH3 (68 mg, 0.182 mmol, 51%). 
LC-MS (ESI+) Rt: 2.37 min (254 nm, Method 1); (m/z): 372.8 [M(35Cl)+H]+ 1H NMR (400 MHz, 
DMSO-d6) δ: 11.23 (s, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.43 (d, J = 2.4 Hz, 1H), 7.37 (dd, J = 8.2, 
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2.3 Hz), 7.36-7.32 (br.s, 2H), 6.93 (s, 1H), 6.79 (d, J = 11.6 Hz, 1H), 6.76 (d, J = 11.8 Hz, 1H), 
5.22 (s, 1H), 3.16 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 169.9, 163.2, 151.1, 142.8, 137.0, 
134.0, 133.2, 131.7, 131.0, 129.4, 128.2, 126.0, 122.2, 117.3, 108.9, 43.9, 36.1 
5-(7-Chloro-2-(phenylamino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (46). A stirred solution of 43 (75 mg, 0.191 mmol) and 
aniline (0.07 mL, 0.76 mmol) dissolved in 1,4-dioxane (2 mL) were treated with conc. HCl (ca. 2 
drops) and heated with stirring in the MW at 1400C for 1h. This was evaporated directly onto silica 
and purified by FC (2-5% MeOH/DCM w. 0.1% 880 NH3) affording the title compound 46 at 3% 
MeOH/DCM w. 0.1% 880 NH3, a pale yellow solid (63 mg, 0.14 mmol, 74%). LC-MS (ESI+) Rt: 
2.92 min (254 nm, Method 1); (m/z): 448.9 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ:  
11.46-11.03 (br.s, 1H), 10.73-10.19 (br.s, 1H), 7.61 (d, J = 7.7 Hz, 2H), 7.50 (d, J = 8.5 Hz, 1H), 
7.47 (d, J = 2.1 Hz, 1H), 7.40 (dd, J = 8.3, 2.2 Hz, 1H), 7.33 (app.t, J = 7.9 Hz, 2H), 7.13 (s, 1H), 
6.98 (t, J = 7.4 Hz, 1H), 6.94-6.88 (m, 2H), 5.29 (s, 1H), 3.19 (s, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ: 164.3, 151.3, 147.6, 143.52, 141.1, 137.0, 134.4, 132.7, 131.1, 129.5, 129.4, 128.6, 
127.75, 127.73, 122.2, 121.9, 118.5, 117.8, 108.8, 43.6, 36.2. 
5-(2-(benzylamino)-7-chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (47). Following General Procedure 1, 43 (75 mg, 0.191 
mmol) was reacted with benzylamine (0.08 mL, 0.76 mmol) to afford the title compound 47 at 4% 
MeOH/DCM w. 0.1% 880 NH3 a pale yellow solid (45 mg, 0.097 mmol, 51%). LC-MS (ESI+) 
Rt: 2.81 min (254 nm, Method 1); (m/z): 462.9 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 
11.25 (s, 1H, s, 1H), 8.41 (t, J = 5.8 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 2.3 Hz, 1H), 
7.38-7.32 (m, 5H), 7.29-7.24 (m, 1H), 7.03 (s, 1H), 6.82 (d, J = 11.6 Hz, 1H), 6.78 (d, J = 11.7 
Hz, 1H), 5.22 (s, 1H), 4.50 (dd, J = 15.2, 5.8 Hz, 1H), 4.42 (dd, J = 15.3, 5.8 Hz, 1H), 3.16 (s, 
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3H). 13C NMR (101 MHz, DMSO-d6) δ: 169.6, 163.3, 151.1, 147.8, 143.1, 139.0, 137.0, 134.2, 
132.9, 131.0, 129.3, 128.8, 128.3, 128.0, 127.6, 126.2, 122.2, 117.2, 108.9, 48.1, 43.8, 36.2. 
5-(7-Chloro-2-(phenethylamino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (48). Following General Procedure 1, 43 (75 mg, 0.191 
mmol) was reacted with phenethylamine (0.10 mL, 0.76 mmol) to afford the title compound 48 at 
3% MeOH/DCM w. 0.1% 880 NH3 a pale yellow solid (51 mg, 0.10 mmol, 54%). LC-MS (ESI+) 
Rt: 2.82 min (254 nm, Method 1); (m/z): 477.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 
11.23 (s, 1H), 8.00 (t, J = 5.4 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 2.2 Hz, 1H), 7.36 
(dd, J = 8.3, 2.3 Hz, 1H), 7.31-7.23 (m, 4H), 7.19 (tt, J = 6.9, 2.0 Hz, 1H), 6.98 (s, 1H), 6.80 (d, J 
= 11.6 Hz, 1H), 6.76 (d, J = 11.8 Hz, 1H), 5.22 (s, 1H), 3.49-3.41 (m, 2H), 3.15 (s, 3H), 2.86 (t, J 
= 7.3 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ: 169.5, 163.3, 151.1, 148.0, 143.0, 139.7, 137.1, 
134.1, 133.1, 131.0, 129.32, 129.16, 128.8, 128.2, 126.6, 126.1, 122.2, 116.8, 108.9, 46.2, 43.9, 
36.2, 35.1. 
5-(7-Chloro-2-(4-methylpiperazin-1-yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (49). Following General Procedure 1, 43 (75 mg, 0.191 
mmol) was reacted with N-methylpiperazine (0.08 mL, 0.76 mmol) to afford the title compound 
49 at 6% MeOH/DCM w.0.1% 880 NH3 a pale yellow solid (64 mg, 0.14 mmol, 71%). LC-MS 
(ESI+) Rt: 2.13 min (254 nm, Method 1); (m/z): 456.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-
d6) δ: 11.25 (s, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.45 (d, J = 2.2 Hz, 1H), 7.38 (dd, J = 8.3, 2.3 Hz, 
1H), 6.96 (s, 1H), 6.88 (d, J = 11.6 Hz, 1H), 6.82 (d, J = 11.7 Hz, 1H), 5.29 (s, 1H), 3.46-3.42 (m, 
4H), 3.16 (s, 3H), 2.52-2.47 (m, 4H), 2.29-2.25 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 171.0, 
163.2, 151.1, 148.3, 142.9, 136.8, 134.2, 133.2, 131.1, 129.5, 128.4, 126.8, 121.9, 118.7, 108.7, 
53.9, 47.8, 45.8, 44.1, 36.2. 
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5-(7-Chloro-2-morpholino-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (50). Following General Procedure 1, 43 (75 mg, 0.191 
mmol) was reacted with morpholine (0.07 mL, 0.76 mmol) to afford the title compound 50 at 3% 
MeOH/DCM w.0.1% 880 NH3 as a pale yellow solid (65 mg, 0.147 mmol, 77%). LC-MS (ESI+) 
Rt: 2.70 min (254 nm, Method 1); (m/z): 443.1 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 
11.25 (s, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.39 (dd, J = 8.3, 2.3 Hz, 1H), 
6.97 (s, 1H), 6.89 (d, J = 11.6 Hz, 1H), 6.83 (d, J = 11.7 Hz, 1H), 5.29 (s, 1H), 3.70 (t, J = 4.9 Hz, 
4H), 3.40 (t, J = 4.8 Hz, 4H), 3.16 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 171.4, 163.3, 151.1, 
148.2, 142.9, 136.8, 134.2, 133.2, 131.1, 129.5, 128.4, 126.9, 121.9, 118.7, 108.7, 65.8, 49.1, 48.2, 
36.2. 
5-(7-Chloro-2-(piperidin-1-yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (51). Following General Procedure 1, 43 (75 mg, 0.191 
mmol) was reacted with piperidine (0.08 mL, 0.76 mmol) to afford the title compound 51 at 3% 
MeOH/DCM w.0.1% 880 NH3 as a pale yellow solid (60 mg, 0.136 mmol, 71%). LC-MS (ESI+) 
Rt: 2.88 min (254 nm, Method 1); (m/z): 441.2 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 
11.23 (s, 1H), 7.46 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 2.2 Hz, 1H), 7.36 (dd, J = 8.3, 2.3 Hz, 1H), 
6.94 (s, 1H), 6.84 (d, J = 11.6 Hz, 1H), 6.78 (d, J = 11.7 Hz, 1H), 5.26 (s, 1H), 3.43-3.40 (m, 4H), 
3.14 (s, 3H), 1.58 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ: 171.1, 163.3, 151.1, 148.5, 142.8, 
136.9, 134.1, 133.3, 131.1, 129.4, 128.3, 126.3, 122.0, 118.0, 108.7, 49.2, 44.1, 36.2, 25.1, 23.9. 
5-(7-Chloro-2-((2-methoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (52). Following General Procedure 1, 43 (75 mg, 0.191 
mmol) was reacted with 2-methoxyethylamine (0.07 mL, 0.76 mmol) to afford the title compound 
52 at 4% MeOH/DCM w.0.1% 880 NH3 as a pale yellow solid (55mg, 0.128 mmol, 67%). LC-
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MS (ESI+) Rt: 2.51 min (254 nm, Method 1); (m/z): 430.9 [M(35Cl)+H]+. 1H NMR (400 MHz, 
DMSO-d6) δ: 11.23 (s, 1H), 7.98 (t, J = 5.3 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.42 (d, J = 2.3 Hz, 
1H), 7.36 (dd, J = 8.3, 2.3 Hz, 1H), 6.99 (s, 1H), 6.79 (d, J = 11.6 Hz, 1H), 6.76 (d, J = 11.8 Hz, 
1H), 5.21 (s, 1H), 3.48-3.45 (m, 2H), 3.26 (s, 3H), 3.24-3.23 (m, 2H), 3.15 (s, 3H). 13C NMR (101 
MHz, DMSO-d6) δ: 169.6, 163.3, 161.6, 151.1, 147.8, 143.0, 137.0, 134.1, 131.0, 129.3, 128.2, 
126.1, 122.3, 116.9, 108.8, 70.6, 58.4, 44.2, 43.9, 36.1. 
5-(7-Chloro-2-((3-methoxypropyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (53).  Following General Procedure 1, 43 (50 mg, 0.127 
mmol) was reacted with 3-methoxypropylamine (0.05 mL, 0.51 mmol) to afford the title 
compound 53 which was isolated at 5% MeOH/DCM, a pale yellow solid (52 mg, 0.117 mmol, 
92%). LC-MS (ESI+) Rt: 2.54 min (254 nm, Method 1); (m/z): 445.1 [M(35Cl)+H]+. 1H NMR (400 
MHz, DMSO-d6) δ: 11.23 (s, 1H), 7.90 (t, J = 5.5 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.42 (d, J = 
2.2 Hz, 1H), 7.35 (dd, J = 8.3, 2.3 Hz, 1H), 7.00 (s, 1H), 6.80 (d, J = 11.6 Hz, 1H), 6.75 (d, J = 
11.7 Hz, 1H), 5.21 (s, 1H), 3.37 (t, J = 6.2 Hz, 2H), 3.28-3.23 (m, 2H), 3.22 (s, 3H), 3.15 (s, 3H), 
1.76 (app.qi, J = 6.5 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ: 169.7, 163.3, 151.1, 148.0, 143.0, 
137.0, 134.1, 133.0, 131.0, 129.3, 128.2, 126.0, 122.3, 116.7, 108.9, 69.8, 58.4, 43.9, 41.9, 36.1, 
29.2. 
5-(7-Chloro-2-((2-ethoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (54). Following General Procedure 1, 43 (50 mg, 0.127 
mmol) was reacted with 2-ethoxyethylamine (0.05 mL, 0.51 mmol) to afford the title compound 
54 at 5% MeOH/DCM, a pale yellow solid (51 mg, 0.115 mmol, 90%). LC-MS (ESI+) Rt: 2.60 
min (254 nm, Method 1); (m/z): 445.1 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 11.24 (s, 
1H), 7.98 (t, J = 5.5 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 2.3 Hz, 1H), 7.37 (dd, J = 8.3, 
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2.3 Hz, 1H), 7.01 (s, 1H), 6.81 (d, J = 11.6 Hz, 1H), 6.77 (d, J = 11.7 Hz, 1H), 5.23 (s, 1H), 3.51 
(t, J = 5.7 Hz, 2H), 3.45 (q, J = 7.0 Hz, 2H), 3.43-3.37 (m, 2H), 3.17 (s, 3H), 1.11 (t, J = 7.0 Hz, 
3H). 13C NMR (101 MHz, DMSO-d6) δ: 169.6, 163.3, 151.1, 147.8, 143.0, 137.0, 134.1, 133.1, 
131.0, 129.3, 128.2, 126.1, 122.3, 116.9, 108.9, 68.5, 65.9, 44.5, 43.9, 36.1, 15.6. 
5-(7-Chloro-2-((2-isopropoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (55). Following General Procedure 1, 43 (50 mg, 0.127 
mmol) was reacted with 2-isopropoxyethylamine (0.06 mL, 0.51 mmol) to afford the title 
compound 55 which was isolated at 5% MeOH/DCM, a pale yellow solid (49 mg, 0.107 mmol, 
84%). LC-MS (ESI+) Rt: 2.68 min (254 nm, Method 1); (m/z): 459.2 [M(35Cl)+H]+. 1H NMR (400 
MHz, DMSO-d6) δ: 11.24 (s, 1H), 7.94 (t, J = 5.5 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 
2.1 Hz, 1H), 7.37 (dd, J = 8.3, 2.2 Hz, 1H), 7.00 (s, 1H), 6.81 (d, J = 11.6 Hz, 1H), 6.77 (d, J = 
11.7 Hz, 1H), 5.23 (s, 1H), 3.57 (sep., J = 6.1 Hz, 1H), 3.52-3.49 (m, 2H), 3.42-3.36 (m, 2H), 3.16 
(s, 3H), 1.09 (d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, DMSO-d6) δ: 169.6, 163.3, 151.1, 147.8, 
143.0, 137.0, 134.1, 133.1, 131.0, 129.3, 128.2, 126.0, 122.3, 116.9, 108.9, 71.3, 66.1, 44.9, 43.9, 
36.1, 22.51, 22.49. 
5-(7-Chloro-2-((2-phenoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-1-
methylpyrimidine-2,4(1H,3H)-dione (56). Following General Procedure 1, 43 (50 mg, 0.127 
mmol) was reacted with 2-phenoxyethylamine (0.07 mL, 0.51 mmol) to afford the title compound 
56 at 4% MeOH/DCM, a pale yellow solid (53 mg, 0.108 mmol, 85%). LC-MS (ESI+) Rt: 2.85 
min (254 nm, Method 1); (m/z): 483.0 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 11.24 (s, 
1H), 8.17 (t, J = 5.5 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.38 (dd, J = 8.3, 
2.2 Hz, 1H), 7.29 (dd, J = 8.5, 7.5 Hz, 2H), 7.00 (s, 1H), 7.01-6.92 (m, 3H), 6.82 (d, J = 11.6 Hz, 
1H), 6.79 (d, J = 11.7 Hz, 1H), 5.26 (s, 1H), 4.13 (t, J = 5.4 Hz, 2H), 3.64 (app.q, J = 5.1 Hz, 2H), 
 55 
3.16 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ: 169.4, 163.3, 158.8, 151.1, 148.3, 147.7, 143.0, 
137.0, 134.1, 131.0, 130.0, 129.4, 128.3, 126.2, 122.2, 117.2, 114.9, 108.8, 66.2, 43.9, 36.1. 
Ethyl 2-((5-(2,7-dichloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)thiazole-4-carboxylate (57). A stirred suspension of 42 
(851 mg, 2.25 mmol) in 1,2-dichloroethane (20 mL) was treated with N,O-
bis(trimethylsilyl)trifluoroacetamide (1.8 mL, 6.75 mmol) and heated to reflux for 18 h. under N2, 
generating an orange solution. This was then treated with ethyl 2-(bromomethyl)thiazole-4-
carboxylate (591 mg, 2.36 mmol) dissolved in 1,2-dichloroethane (3 mL) and refluxed for 72 h. 
This was concentrated in vacuo to a gum, treated with MeOH (20 mL) and then re-concentrated in 
vacuo to a brown solid. This was triturated with diethyl ether (3 x 50 mL) to give the title 
compound 57 a brown solid (1.125 g, 2.06 mmol, 91%). LC-MS (ESI+) Rt: 2.95 min (254 nm, 
Method 1); (m/z): 546.9 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 11.49 (s, 1H), 8.50 (s, 
1H), 7.59 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.51 (dd, J = 8.2, 2.3 Hz, 1H), 7.03 (d, J 
= 11.9 Hz, 1H), 7.03 (d, J = 1.1 Hz, 1H), 6.96 (d, J = 11.7 Hz, 1H), 5.55 (d, J = 0.9 Hz, 1H), 5.20 
(d, J = 15.8 Hz, 1H), 5.16 (d, J = 15.9 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ: 166.6, 162.7, 161.0, 150.67, 150.55, 148.6, 146.4, 142.0, 
136.2, 134.5, 133.3, 132.00, 131.81, 131.5, 130.5, 130.1, 129.7, 120.6, 109.0, 61.4, 48.4, 44.1, 
14.7.  
Ethyl 2-((5-(7-chloro-2-((2-methoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-
4-yl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)thiazole-4-carboxylate (58). 
Following General Procedure 1, 57 (400 mg, 0.73 mmol) was reacted with 2-methoxyethylamine 
(0.25 mL, 2.92 mmol) to afford the title compound 58 at 3% MeOH/DCM, a pale yellow solid 
(250 mg, 0.43 mmol, 59%). LC-MS (ESI+) Rt: 2.69 min (254 nm, Method 1); (m/z): 585.8 
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[M(35Cl)+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 11.46 (s, 1H), 8.51 (s, 1H), 7.97 (t, J = 5.4 Hz, 
1H), 7.46 (d, J = 8.4 Hz, 1H), 7.39 (d, J = 2.1 Hz, 1H), 7.37 (dd, J = 8.1, 2.3 Hz, 1H), 7.18 (s, 
1H), 6.68 (d, J = 11.6 Hz, 1H), 6.65 (d, J = 11.7 Hz, 1H), 5.27 (d, J = 15.9 Hz, 1H), 5.22 (s, 1H), 
5.15 (d, J = 15.9 Hz, 1H), 4.34 (q, J = 7.0 Hz, 2H), 3.46-3.44 (m, 2H), 3.39 (app.q, J = 5.6 Hz, 
2H), 3.25 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ: 169.5, 166.5, 163.0, 
161.0, 150.7, 147.4, 146.3, 141.8, 137.0, 133.8, 133.0, 131.0, 130.6, 129.2, 128.2, 126.0, 122.3, 
116.9, 109.3, 70.6, 61.3, 58.4, 48.5, 44.16, 43.99, 14.7. 
Ethyl 2-((5-(7-chloro-2-((2-methoxyethyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-
4-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)thiazole-4-carboxylate (59). 
Following General Procedure 2, 58 (240 mg, 0.41 mmol) was converted to the title compound 59 
which was isolated at 2% MeOH/DCM, a yellow solid (200 mg, 0.33 mmol, 81%). LC-MS (ESI+) 
Rt: 2.87 min (254 nm, Method 1); (m/z): 601.9 [M(35Cl)+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 
12.87 (s, 1H), 8.55 (s, 1H), 8.02-7.98 (br.s, 1H), 7.74 (s, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.40 (d, J 
= 2.3 Hz, 1H), 7.36 (dd, J = 8.4, 2.3 Hz, 1H), 6.75 (s, 2H), 5.65 (s, 1H), 5.39 (d, J = 15.8 Hz, 1H), 
5.26 (d, J = 15.8 Hz, 1H), 4.35 (q, J = 7.0 Hz, 2H), 3.42-3.40 (m, 2H), 3.37-3.35 (m, 2H), 3.23 (s, 
3H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ: 189.8, 169.3, 165.5, 161.0, 147.9, 
146.4, 141.9, 137.5, 133.7, 132.1, 130.93, 130.81, 128.9, 127.8, 126.7, 122.7, 117.6, 116.7, 70.6, 
61.4, 58.4, 49.2, 45.3, 44.1, 14.7. 
3-((5-(2,8-Dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-5-(methoxycarbonyl)benzoic acid (61) and 5-((5-(2,8-
dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)isophthalic acid (60). Step a) N,O-bis(trimethylsilyl)trifluoroacetamide (0.76 g, 2.96 
mmol) was added to a stirred suspension of  5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-
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yl)pyrimidine-2,4(1H,3H)-dione (patent: US6107297) (0.49 g, 1.48 mmol) in 1,2-dichloroethane 
(6 mL) and the reaction mixture heated under reflux, under nitrogen. After 1.5 h, dimethyl 5-
(bromomethyl)isophthalate (0.43 g, 1.48 mmol) was added. The reaction mixture was heated under 
reflux for a further 16 h.  After cooling the volatiles were removed under vacuum. Purification was 
by silica gel chromatography eluting with ethyl acetate:petroleum ether, 50:50 to give dimethyl 5-
((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)isophthalate Yield 0.7 g, 1.3 mmol, 87%. LC-MS (ESI+) Rt 3.10 (254nm, method 1); 
(m/z): 537.2 (M+1). Step b) Lawesson’s reagent (0.8 g, 2 mmol) and the product from step a) (0.7 
g, 1.3 mmol) in 1,4-dioxane (8 mmol) was heated under reflux, under nitrogen. After 16h, the 
volatiles were evaporated under vacuum. Purification was by silica gel chromatography eluting 
with ethyl acetate:toluene, 30:70 to give dimethyl 5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)isophthalate Yield 0.4 g, 0.72 mmol, 55% as a yellow solid. LC-MS (ESI+) Rt 3.19 (254 
nm, method 1); (m/z): 553.7 (M+1). Step c) Sodium hydroxide solution (0.4 mmol, 0.4 mL of 1M 
solution in water) was added to a mixture of the product from step b) (0.11 g, 0.2 mmol) in 
methanol (1 mL), toluene (0.5 mL) and water (0.5 mL). After 4h, reaction mixture was partitioned 
between 2M Hydrochloric acid and ethyl acetate. The ethyl acetate layer was washed with brine, 
dried (magnesium sulphate), filtered and evaporated in vacuo. Purification was by silica gel 
chromatography eluting with 2% acetic acid in ethyl acetate:toluene, 25:75 then 2% acetic acid in 
ethyl acetate:toluene, 80:20. Yield of (61) 0.07 g, 0.13 mmol, 65% as a yellow solid. 1H NMR 
(400 MHz, DMSO) δ 13.47 (s, 1H), 12.62 (s, 1H), 8.49 (tt, J = 3.9, 1.7 Hz, 1H), 8.12 (td, J = 13.7, 
1.6 Hz, 2H), 7.45 (d, J = 7.8 Hz, 2H), 7.15 (dd, J = 7.9, 1.9 Hz, 2H), 7.09 (td, J = 5.1, 1.9 Hz, 2H), 
7.02 (s, 1H), 6.70 (s, 2H), 5.72 (s, 1H), 4.99 (t, J = 4.0 Hz, 2H), 3.97 (s, 3H), 2.27 (s, 6H). LC-MS 
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(ESI+) Rt 3.05 (254nm); (m/z): 539.6 (M+1). Yield of (60) 0.02 g, 0.038 mmol, 19% as a yellow 
solid. 1H NMR (400 MHz, DMSO) δ 13.47 (s, 2H), 12.62 (s, 1H), 8.49 (q, J = 2.0 Hz, 1H), 8.09 
(d, J = 1.6 Hz, 2H), 7.45 (d, J = 7.9 Hz, 2H), 7.15 (dd, J = 7.9, 1.9 Hz, 2H), 7.07 (d, J = 1.9 Hz, 
2H), 7.02 (s, 1H), 6.70 (s, 2H), 5.72 (s, 1H), 4.98 (s, 2H), 2.27 (s, 6H). LC-MS (ESI+) Rt 2.81 
(254nm, method 1); (m/z): 525.2 (M+1). 
Methyl 3-((2-((tert-butoxycarbonyl)amino)ethyl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)benzoate (62). PyBroP® (0.19 g, 0.4 mmol) was added to a stirred solution of 3-((5-
(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)-5-(methoxycarbonyl)benzoic acid (0.15 g, 0.28 mmol), tert-butyl (2-
aminoethyl)carbamate (0.058 g, 0.36 mmol) and triethylamine (0.15 g, 1.5 mmol) in DMF (2 ml). 
After 0.5 h, the solution was diluted with ethyl acetate (15 mL) and washed with water (2x4 mL) 
and brine (1x4 mL). The solution was evaporate to dryness under reduced pressure. Purification 
was by silica gel chromatography eluting with ethyl acetate: 40-60 petroleum ether, 70:30. Yield 
0.1 g, 0.15 mmol, 53% as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.47 (s, 1H), 8.50 (s, 1H), 
8.04 (dt, J = 7.1, 1.8 Hz, 2H), 7.63 – 7.58 (m, 1H), 7.50 (d, J = 7.8 Hz, 2H), 7.16 (dd, J = 7.9, 1.5 
Hz, 1H), 7.07 (s, 1H), 6.90 (s, 1H), 6.68 (s, 2H), 5.74 (s, 1H), 5.33 (s, 1H), 5.10 – 5.05 (m, 1H), 
4.79 (s, 2H), 4.02 (s, 3H), 3.68 – 3.60 (m, 2H), 3.50 – 3.44 (m, 2H), 2.32 (s, 6H), 1.44 (s, 8H). LC-
MS (ESI+) Rt 3.14 (254nm, method 1); (m/z): 681.2 (M+1) 
Methyl 3-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)-5-((5-(2,8-
dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)benzoate (63). PyBroP® (0.11 g, 0.24 mmol) was added to a stirred solution of 3-((5-
(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
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yl)methyl)-5-(methoxycarbonyl)benzoic acid (0.1 g, 0.186 mmol), tert-butyl (2-(2-(2-
aminoethoxy)ethoxy)ethyl)carbamate (0.05 g , 0.2 mmol) and triethylamine (0.1 g, 1 mmol) in 
DMF (2 mL). After 0.5 h, the solution was diluted with ethyl acetate (15 ml) and washed with 
water (2x4 mL) and brine (1x4 mL). The solution was evaporate to dryness under reduced pressure. 
Purification was by silica gel chromatography eluting with ethyl acetate. Yield 0.09 g, 0.12 mmol, 
63% as a yellow solid. 1H NMR (400 MHz, DMSO) δ 12.61 (s, 1H), 8.89 (t, J = 5.5 Hz, 1H), 8.48 
(t, J = 1.6 Hz, 1H), 8.05 (t, J = 1.7 Hz, 1H), 8.00 (t, J = 1.6 Hz, 1H), 7.44 (d, J = 7.9 Hz, 2H), 7.14 
(ddd, J = 7.8, 1.9, 0.8 Hz, 2H), 7.05 (dd, J = 1.9, 0.8 Hz, 2H), 6.94 (s, 1H), 6.76 (t, J = 5.6 Hz, 1H), 
6.62 (s, 2H), 5.71 (s, 1H), 4.95 (s, 2H), 3.97 (s, 3H), 3.65 – 3.56 (m, 4H), 3.56 – 3.47 (m, 4H), 
3.39 (t, J = 12.3 Hz, 1H), 3.33 – 3.30 (m, 1H), 3.07 (q, J = 6.0 Hz, 2H), 2.27 (s, 6H), 1.37 (s, 9H). 
LC-MS (ESI+) Rt 3.19 (254nm, method 1); (m/z): 769.6 (M+1) 
tert-Butyl (2-(3-((2H-tetrazol-5-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)benzamido)ethyl)carbamate (64). 
Lithium hydroxide (0.04 g, 1.6 mmol) in water (0.5 mL) was added to a stirred solution of methyl 
3-((2-((tert-butoxycarbonyl)amino)ethyl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzoate 
(0.1 g, 0.15 mmol) in methanol (1.5 mL). After 16h, the mixture was partitioned between ethyl 
acetate and 2M hydrochloric acid solution. The ethyl acetate solution was washed with brine, dried 
(magnesium sulphate), filtered and evaporated in vacuo to give 3-((2-((tert-
butoxycarbonyl)amino)ethyl)carbamoyl)-5-((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-
2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzoic acid. Yield 0.08 g, as a yellow 
solid. LC-MS (ESI+) Rt 2.99 (254nm, method 1); (m/z): 667.5 (M+1) 
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PyBroP® (0.16 g, 0.34 mmol) was added to a stirred solution of 3-((2-((tert-
butoxycarbonyl)amino)ethyl)carbamoyl)-5-((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-
yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzoic acid (0.09 g, 0.135 mmol), 
5-aminotetrazole monohydrate (0.055 g , 0.54 mmol) and triethylamine (0.13 g, 1.3 mmol) in 
DMF (2 ml). After 0.5 h, the solution was diluted with ethyl acetate (15 mL) and washed with 
2M hydrochloric acid (1x4 mL), water (2x4 mL) and brine (1x4 mL). The solution was 
evaporate to dryness under reduced pressure. Purification was by silica gel chromatography 
eluting with methanol:dichloromethane, 5:95 and then  2% acetic acid in 
methanol:dichloromethane, 5:95 . Yield 0.03 g, 0.04 mmol, 30% as a yellow solid. 1H NMR 
(400 MHz, DMSO) δ 12.66 – 12.59 (m, 1H), 12.45 – 11.87 (m, 1H), 8.83 – 8.67 (m, 1H), 8.57 
– 8.43 (m, 1H), 8.09 – 7.94 (m, 2H), 7.49 – 7.41 (m, 2H), 7.31 – 7.23 (m, 1H), 7.22 – 7.17 (m, 
2H), 7.14 – 7.10 (m, 1H), 7.04 – 7.00 (m, 1H), 6.99 – 6.89 (m, 1H), 6.67 – 6.48 (m, 2H), 5.75 – 
5.69 (m, 1H), 5.03 – 4.88 (m, 2H), 3.44 – 3.33 (m, 2H), 3.24 – 3.09 (m, 2H), 2.30 – 2.20 (m, 
6H), 1.38 (s, 9H).LC-MS (ESI+) Rt 2.98 (254nm, method 1); (m/z): 734.3 (M+1) 
tert-Butyl (2-(2-(2-(3-((2H-tetrazol-5-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)benzamido)ethoxy)ethoxy)ethyl)carbamate (65). 
Lithium hydroxide (0.04 g, 1.6 mmol) in water (0.5 mL) was added to a stirred solution of methyl 
3-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzoate 
(0.035 g, 0.046 mmol) in methanol (1.5 mL). After 16h, the mixture was partitioned between ethyl 
acetate and 2M hydrochloric acid solution. The ethyl acetate solution was washed with brine, dried 
(magnesium sulphate), filtered and evaporated in vacuo to give 3-((2,2-dimethyl-4-oxo-3,8,11-
 61 
trioxa-5-azatridecan-13-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-
oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzoic acid.  Yield 0.032 g, as a yellow 
solid. 1H NMR LC-MS (ESI+) Rt 3.04 (254nm, method 1); (m/z): 755.6 (M+1). PyBroP® (0.042 
g, 0.09 mmol) was added to a stirred solution of 3-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-
azatridecan-13-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-
thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzoic acid (0.05 g, 0.067 mmol), 5-
aminotetrazole monohydrate (0.02 g , 0.2 mmol) and triethylamine (0.03 g, 0.3 mmol) in DMF (1 
mL). After 0.5 h, the solution was diluted with ethyl acetate (15 mL) and washed with 2m 
hydrochloric acid (1x4 mL), water (2x4 mL) and brine (1x4 mL). The solution was evaporate to 
dryness under reduced pressure. Purification was by silica gel chromatography eluting with 
methanol:dichloromethane, 5:95 and then  2% acetic acid in methanol:dichloromethane, 5:95 . 
Yield 0.009 g, 0.01 mmol, 14% as a yellow solid. 1H NMR (400 MHz, DMSO) δ 12.64 (s, 1H), 
12.51 (s, 1H), 8.76 (t, J = 5.6 Hz, 1H), 8.57 (s, 1H), 8.03 (d, 1H), 7.44 (d, J = 7.9 Hz, 2H), 7.12 
(dd, J = 8.1, 1.9 Hz, 2H), 7.00 (d, J = 1.9 Hz, 2H), 6.90 (s, 1H), 6.79 – 6.73 (m, 1H), 6.54 (s, 2H), 
5.73 (s, 1H), 4.97 (s, 2H), 3.71 – 3.57 (m, 4H), 3.54 (dd, J = 6.1, 4.1 Hz, 4H), 3.40 (d, J = 6.7 Hz, 
2H), 3.07 (q, J = 6.0 Hz, 2H), 2.22 (s, 6H), 1.37 (s, 9H). LC-MS (ESI+) Rt 3.02 (254nm, method 
1); (m/z): 822.3 (M+1) 
(E)-N1-(2-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetamido)ethyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-N3-
(1H-tetrazol-5-yl)isophthalamide (66). Following General Procedure 3 with tert-butyl (2-(3-
((2H-tetrazol-5-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-
thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzamido)ethyl)carbamate (3.2 mg, 4.3x10-3 
 62 
mmol) and 2,5-dioxopyrrolidin-1-yl (E)-2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetate (2.3 mg, 4.2x10-3 mmol). 
Yield 0.67 mg, 0.627x10-3 mmol, 15%. LC-MS (ESI+) Rt 3.19 (254nm); (m/z): 1066.4 (M+1). 
(E)-N1-(2-(6-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetamido)hexanamido)ethyl)-5-((5-(2,8-dimethyl-
5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-
N3-(1H-tetrazol-5-yl)isophthalamide (67). Following General Procedure 3 with tert-butyl (2-(3-
((2H-tetrazol-5-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-
thioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzamido)ethyl)carbamate (2.2 mg, 3x10-3 
mmol) and 2,5-dioxopyrrolidin-1-yl (E)-6-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetamido)hexanoate (2.0 mg, 
3x10-3 mmol). Yield 1.2 mg, 1x10-3 mmol, 45%. LC-MS (ESI+) Rt 7.35 (254nm); (m/z): 1179.4 
(M+1).  
(E)-N1-(2-(2-(2-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetamido)ethoxy)ethoxy)ethyl)-5-((5-(2,8-
dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)-N3-(1H-tetrazol-5-yl)isophthalamide (68). Following General Procedure 3, with 
tert-butyl (2-(2-(2-(3-((2H-tetrazol-5-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)benzamido)ethoxy)ethoxy)ethyl)carbamate (3.4 mg, 4.14x10-3 mmol) and 2,5-
dioxopyrrolidin-1-yl (E)-2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetate (2.26 mg, 4.14x10-3 mmol). Yield 0.7 
mg, 0.67x10-3 mmol, 17%. LC-MS (ESI+) Rt 7.46 (254nm); (m/z): 1154.6 (M+1). 
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(E)-N1-(18-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)-10,17-dioxo-3,6-dioxa-9,16-diazaoctadecyl)-5-((5-
(2,8-dimethyl-5H-dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-
1(2H)-yl)methyl)-N3-(1H-tetrazol-5-yl)isophthalamide (69). 4M HCl in 1,4-dioxane (1 mL) 
was added to tert-butyl (2-(2-(2-(3-((2H-tetrazol-5-yl)carbamoyl)-5-((5-(2,8-dimethyl-5H-
dibenzo[a,d][7]annulen-5-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)benzamido)ethoxy)ethoxy)ethyl)carbamate (1.5 mg, 1.82x10-3 mmol). The solution was 
stirred for 2h and then evaporated to dryness in vacuo.  DMF (0.5 mL) was added and to this 
solution was added di-isopropylethylamine (10 mg) and then 2,5-dioxopyrrolidin-1-yl (E)-6-(2-
(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)hexanoate (1.2 mg, 1.8x10-3 mmol). The reaction mixture was stirred 
in the dark and under nitrogen overnight. Purification was by reverse phase preparative HPLC 
eluting with a gradient of 50 to 60 % MeCN in water (0.1% formic acid) over 20 min. The fraction 
containing the product was lyophilised. Yield 1.002mg, 0.79x10-3 mmol, 41%. LC-MS (ESI+) Rt 
7.41 (254nm); (m/z): 1267.0 (M+1). 
tert-Butyl 3-((7-chloro-4-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanoate (70). Following General Procedure 
1, 43 (200 mg, 0.51 mmol) was reacted with β-alanine-tert-butyl ester hydrochloride (370 mg, 2.04 
mmol) to afford the title compound 70 which was isolated at 5% MeOH/DCM, a pale yellow solid 
(248 mg, 0.494 mmol, 96%). LC-MS (ESI+) Rt: 2.79 min (254 nm, Method 1); (m/z): 500.9 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 11.20 (s, 1H), 7.97 (t, J = 5.5 Hz, 1H), 7.46 (d, 
J = 8.4 Hz, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.38 (dd, J = 8.3, 2.3 Hz, 1H), 7.03 (s, 1H), 6.82 (d, J 
= 11.6 Hz, 1H), 6.79 (d, J = 11.7 Hz, 1H), 5.22 (s, 1H), 3.48-3.42 (m, 2H), 3.17 (s, 3H), 1.39 (s, 
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9H). 13C NMR (101 MHz, DMSO-d6) δ: 171.0, 169.3, 163.3, 151.1, 147.8, 143.1, 137.0, 134.2, 
133.14, 133.00, 132.96, 131.0, 126.2, 122.2, 117.0, 108.9, 80.5, 43.8, 40.5, 36.2, 35.2, 28.2.  
tert-Butyl 6-((7-chloro-4-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)hexanoate (71). Following General Procedure 
1, 43 (200 mg, 0.51 mmol) was reacted with tert-butyl 6-aminohexanoate (382 mg, 2.04 mmol) to 
afford the title compound 71 at 5% MeOH/DCM, a pale yellow solid (248 mg, 0.494 mmol, 97%). 
LC-MS (ESI+) Rt: 2.91 min (254 nm, Method 1); (m/z): 543.0 [M(35Cl)+H]+. 1H NMR (400 MHz, 
DMSO-d6) δ: 11.24 (s, 1H), 7.92 (t, J = 5.4 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 2.2 Hz, 
1H), 7.37 (dd, J = 8.3, 2.2 Hz, 1H), 7.01 (s, 1H), 6.81 (d, J = 11.6 Hz, 1H), 6.76 (d, J = 11.7 Hz, 
1H), 5.23 (s, 1H), 3.22-3.15 (m, 2H), 3.17 (s, 3H), 2.18 (t, J = 7.3 Hz, 2H), 1.56-1.49 (m, 4H), 
1.38 (s, 9H), 1.34-1.30 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ: 172.7, 169.8, 163.3, 151.1, 
148.0, 142.9, 137.1, 134.1, 133.1, 131.0, 129.3, 128.2, 125.9, 122.3, 116.6, 108.9, 79.8, 44.6, 43.9, 
36.2, 35.2, 28.7, 28.2, 26.3, 24.8. 
3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanoic acid (72). Following General 
Procedure 2, 70 (200 mg, 0.40 mmol) was converted to the thiouracil which was isolated at 2% 
MeOH/DCM, a yellow solid (124 mg). The intermediate product (100 mg, 0.193 mmol) was 
dissolved in DCM (12 mL) and was treated with trifluoroacetic acid (6 mL) and stirred at RT for 
30 min until completion was observed by TLC. The RM was diluted with toluene (25 mL) and 
concentrated in vacuo to 1/5th volume; this was repeated 3 times before concentrating to dryness 
to afford a yellow solid. This was purified by FC, washing with 5% MeOH/DCM before eluting 
the title compound off with 20% MeOH/DCM w. 1% acetic acid, affording 72, a yellow solid (34 
mg, 0.074 mmol, 39%). LC-MS (ESI+) Rt: 2.61 min (254 nm, Method 1); (m/z): 460.9 
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[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (s, 1H), 12.45-12.07 (br.s, 1H), 7.99 (t, J 
= 5.2 Hz, 1H), 7.71 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.35 (dd, J = 8.4, 
2.3 Hz, 1H), 6.88 (s, 2H), 5.68 (s, 1H), 3.44 (app.q, J = 6.1 Hz, 2H), 3.31 (s, 3H).  
6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)hexanoic acid (73). Following General 
Procedure 2, 71 (200 mg, 0.40 mmol) was converted to the thiouracil which was isolated at 2% 
MeOH/DCM, a yellow solid (124 mg), which was dissolved in DCM (14 mL) was treated with 
trifluoroacetic acid (7 mL) and stirred at RT for 30 min until completion was observed by TLC. 
The RM was diluted with toluene (25 mL) and concentrated in vacuo to 1/5th volume; this was 
repeated 3 times before concentrating to dryness to afford a yellow solid. This was purified by FC 
washing with 5% MeOH/DCM before eluting the title compound off with 20% MeOH/DCM w. 
1% acetic acid, affording 73, a yellow solid (80 mg, 0.159 mmol, 74%). LC-MS (ESI+) Rt: 2.67 
min (254 nm, Method 1); (m/z): 502.9 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.80-
12.53 (br.s, 1H), 12.16-11.93 (br.s, 1H), 7.94 (t, J = 5.3 Hz, 1H), 7.62 (s, 1H), 7.58 (d, J = 8.5 Hz, 
1H), 7.45 (d, J = 2.3 Hz, 1H), 7.34 (dd, J = 8.4, 2.3 Hz, 1H), 6.86 (s, 2H), 5.71 (s, 1H), 3.29 (s, 
3H), 3.23-3.18 (m, 2H), 2.20 (t, J = 7.3 Hz, 2H), 1.56-1.48 (m, 4H), 1.36-1.29 (m, 2H). 13C NMR 
(101 MHz, DMSO-d6) δ: 189.2, 174.9, 169.6, 149.1, 148.5, 143.3, 137.6, 134.0, 132.0, 130.8, 
129.0, 127.8, 126.58, 126.56, 122.7, 117.5, 116.4, 45.3, 44.7, 37.2, 34.1, 26.5, 24.7. 
tert-Butyl (2-(3-((7-chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-
4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanamido)ethyl)carbamate (74). A 
stirred solution 72 (10 mg, 0.022 mmol) in DMF (1 mL) was treated with DIPEA (50 μL) and N-
Boc-ethylenediamine (21 mg, 0.132 mmol) followed by PyBroP® (15 mg, 0.033 mmol) and stirred 
at RT for 1h. until completion was observed by LC-MS. The RM was quenched with water (c.a. 2 
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drops) and concentrated in vacuo azeotroping with toluene (2 x 25 mL) to afford an orange oil. 
This was purified by FC (1-5% MeOH/DCM) affording the title compound 74 at 4% MeOH/DCM, 
a yellow solid (5.2 mg, 0.0086 mmol, 39%). LC-MS (ESI+) Rt: 2.75 min (254 nm, Method 1); 
(m/z): 603.1 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.67 (s, 1H), 7.95 (t, J = 5.5 Hz, 
1H), 7.91 (t, J = 5.4 Hz, 1H), 7.74 (s, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.35 
(dd, J = 8.4, 2.3 Hz, 1H), 6.88 (s, 2H), 6.78 (t, J = 5.3 Hz, 1H), 5.66 (s, 1H), 3.45 (app.q, J = 6.5 
Hz, 2H), 3.32 (s, 3H), 3.07-3.03 (m, 2H), 2.96 (app.q, J = 6.1 Hz, 2H), 2.38 (t, J = 6.8 Hz, 2H), 
1.38 (s, 9H). 
tert-Butyl (2-(6-((7-chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-
4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)hexanamido)ethyl)carbamate (75). A 
stirred solution 73 (30 mg, 0.060 mmol) in DMF (3 mL) was treated with DIPEA (150 μL) and N-
Boc-ethylenediamine (58 mg, 0.362 mmol) followed by PyBroP® (42 mg, 0.090 mmol) and stirred 
at RT for 1 h. until completion was observed by LC-MS. The RM was quenched with water (c.a. 
2 drops) and concentrated in vacuo azeotroping with toluene (2 x 25 mL) to afford an orange oil. 
This was purified by FC (1-5% MeOH/DCM) affording the tile compound 75 at 4% MeOH/DCM 
(15 mg, 0.023 mmol, 39%). LC-MS (ESI+) Rt: 2.80 min (254 nm, Method 1); (m/z): 645.1 
[M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (s, 1H), 7.93 (t, J = 5.4 Hz, 1H), 7.78-
7.77 (m, 1H), 7.62 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.34 (dd, J = 8.4, 
2.3 Hz, 1H), 6.86 (s, 2H), 6.77 (t, J = 5.5 Hz, 1H), 5.71 (s, 1H), 3.29 (s, 3H), 3.22-3.17 (m, 2H), 
3.05 (app.q, J = 5.8 Hz, 2H), 2.98-2.94 (m, 2H), 2.04 (t, J = 7.3 Hz, 2H), 1.55-1.47 (m, 4H), 1.37 
(s, 9H), 1.31 (t, J = 7.6 Hz, 2H). 
tert-Butyl (2-(2-(2-(3-((7-chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-
5-yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-
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yl)amino)propanamido)ethoxy)ethoxy)ethyl)carbamate (76). A stirred solution 72 (10 mg, 
0.022 mmol) in DMF (1 mL) was treated with DIPEA (50 μL) and N-Boc-2,2′-
(ethylenedioxy)diethylamine (33 mg, 0.132 mmol) followed by PyBroP® (15 mg, 0.033 mmol) 
and stirred at RT for 1h. until completion was observed by LC-MS. The RM was quenched with 
water (c.a. 2 drops) and concentrated in vacuo azeotroping with toluene (2 x 25 mL) to afford an 
orange oil. This was purified by FC (1-5% MeOH/DCM) affording the tile compound 76 at 4% 
MeOH/DCM, a yellow solid (8.8 mg, 0.0127 mmol, 58%). LC-MS (ESI+) Rt: 2.76 min (254 nm, 
Method 1); (m/z): 691.1 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 12.67 (s, 1H), 7.95 (t, 
J = 5.5 Hz, 2H), 7.79 (s, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.34 (dd, J = 8.4, 
2.3 Hz, 1H), 6.88 (s, 2H), 6.76 (t, J = 5.4 Hz, 1H), 5.64 (s, 1H). 
tert-Butyl (2-(2-(2-(6-((7-chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-
5-yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-
yl)amino)hexanamido)ethoxy)ethoxy)ethyl)carbamate (77). A stirred solution 73 (30 mg, 
0.060 mmol) in DMF (3 mL) was treated with DIPEA (150 μL) and N-Boc-ethylenediamine (58 
mg, 0.362 mmol) followed by PyBroP® (42 mg, 0.090 mmol) and stirred at RT for 1 h. until 
completion was observed by LC-MS. The RM was quenched with water (c.a. 2 drops) and 
concentrated in vacuo azeotroping with toluene (2 x 25 mL) to afford an orange oil. This was 
purified by FC (1-5% MeOH/DCM) affording the tile compound 77 at 4% MeOH/DCM (16 mg, 
0.022 mmol, 36%). LC-MS (ESI+) Rt: 2.81 min (254 nm, Method 1); (m/z): 733.2 [M(35Cl)+H]+. 
1H NMR (400 MHz, DMSO-d6) δ: - 12.66 (s, 1H), 7.93 (t, J = 5.4 Hz, 1H), 7.81 (t, J = 5.6 Hz, 
1H), 7.62 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 2.3 Hz, 1H), 7.34 (dd, J = 8.4, 2.3 Hz, 
1H), 6.86 (s, 2H), 6.76 (t, J = 5.0 Hz, 1H), 5.71 (s, 1H), 3.51-3.49 (m, 2H), 3.38 (q, J = 5.3 Hz, 
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6H), 3.29 (s, 3H), 3.22-3.16 (m, 4H), 3.06 (q, J = 6.0 Hz, 2H), 2.06 (t, J = 7.4 Hz, 2H), 1.57-1.52 
(m, 4H), 1.37 (s, 9H), 1.33-1.27 (m, 2H). 
(E)-3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-
yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)ethyl)propanamide (78). Following General Procedure 3, 74 was 
converted to BODIPY®630/650 conjugate 78.  This was purified using preparative RP-HPLC 
(Method 4) isolating 78 at Rt: 13.45 min which was freeze dried to a blue iridescent solid (0.52 
mg, 0.54 μmol, 27%). LC-MS (ESI+) Rt: 3.04 min (254 nm, Method 1); (m/z): 935.1 
[M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C45H39BClF2N8O4S3, 935.2001; found, 
935.2002. [M+Na]+ calcd. for C45H38BClF2N8NaO4S3, 957.1820; found, 957.1838.  
(E)-N-(2-(3-((7-chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanamido)ethyl)-6-(2-(4-(2-(5,5-difluoro-
7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)hexanamide (79). Following General Procedure 3, 74 was 
converted to BODIPY®630/650-X conjugate 79.  This was purified using preparative RP-HPLC 
(Method 4) isolating 173 at Rt: 13.37 min which was freeze dried to a blue iridescent solid (0.85 
mg, 0.81 μmol, 41%). LC-MS (ESI+) Rt: 3.01 min (254 nm, Method 1); (m/z): 1048.2 
[M(35Cl)+H]+. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. for C51H48BClF2N9O5S3, 1046.2694; found, 
1046.2657. 
(E)-N-(2-(2-(2-(3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanamido)ethoxy)ethoxy)ethyl)-
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6-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetamido)hexanamide (80). Following General 
Procedure 3, 76 was converted to BODIPY®630/650-X conjugate 80.  This was purified using 
preparative RP-HPLC (Method 4) isolating 80 at Rt: 13.03 min which was freeze dried to a blue 
iridescent solid (0.57 mg, 0.50 μmol, 25%). LC-MS (ESI+) Rt: 3.01 min (254 nm, Method 1); 
(m/z): 1136.2 [M(35Cl)+H]+. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. for C55H56BClF2N9O7S3, 
1134.3220; found, 1134.3160. 
(E)-6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-
yl)-5H-5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)ethyl)hexanamide (81). Following General Procedure 3, 75 was 
converted to BODIPY®630/650 conjugate 81.  This was purified using preparative RP-HPLC 
(Method 4) isolating 81 at Rt: 13.05 min which was freeze dried to a blue iridescent solid (0.41 
mg, 0.42 μmol, 21%). LC-MS (ESI+) Rt: 3.04 min (254 nm, Method 1); (m/z): 977.2 
[M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C48H45BClF2N8O4S3, 977.2470; found, 
977.2558. [M+Na]+ calcd. for C48H44BClF2N8NaO4S3, 999.2289; found, 999.2380. H.MS-TOF 
(ESI-) (m/z): [M-H]- calcd. for C48H43BClF2N8O4S3, 975.2325; found, 975.2272. 
(E)-6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(2-(2-(2-(4-(2-(5,5-difluoro-7-
(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)ethoxy)ethoxy)ethyl)hexanamide (82). Following General 
Procedure 3, 77 was converted to BODIPY®630/650 conjugate 82.  This was purified using 
preparative RP-HPLC (Method 4) isolating 82 at Rt:13.69 min which was freeze dried to a blue 
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iridescent solid (0.22 mg, 0.21 μmol, 10%). LC-MS (ESI+) Rt: 3.05 min (254 nm, Method 1); 
(m/z): 1065.2 [M(35Cl)+H]+. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. for C52H51BClF2N8O6S3, 
1063.2849; found, 1063.2803. 
(E)-6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(6-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-
yl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)hexanamido)ethyl)hexanamide (83). Following General 
Procedure 3, 75 was converted to BODIPY®630/650-X conjugate 83.  This was purified using 
preparative RP-HPLC (Method 4) isolating 83 at Rt: 13.27 min which was freeze dried to a blue 
iridescent solid (0.39 mg, 0.36 μmol, 18%). LC-MS (ESI+) Rt: 3.02 min (254 nm, Method 1); 
(m/z): 1090.2 [M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C54H56BClF2N9O5S3, 
1090.3311; found, 1090.3293. [M+Na]+ calcd. for C54H55BClF2N9NaO5S3, 1112.3130; found, 
1112.3129. 
(E)-6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(18-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-
5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)-10,17-dioxo-3,6-
dioxa-9,16-diazaoctadecyl)hexanamide (84). Following General Procedure 3, 77 was converted 
to BODIPY®630/650-X conjugate 84.  This was purified using preparative RP-HPLC (Method 4) 
isolating 84 at Rt: 13.28which was freeze dried to a blue iridescent solid (0.47 mg, 0.40 μmol, 
20%). LC-MS (ESI+) Rt: 3.02 min (254 nm, Method 1); (m/z): 1178.2 [M(35Cl)+H]+. H.MS-TOF 
(ESI+) (m/z): [M+H]+ calcd. for C58H64BClF2N9O7S3, 1178.3835; found, 1178.3933. [M+Na]
+ 
calcd. for C58H63BClF2N9NaO7S3, 1200.3654; found, 1200.3772. H.MS-TOF (ESI-) (m/z): [M-H]
- 
calcd. for C58H62BClF2N9O7S3, 1176.3689; found, 1176.3647. 
 71 
3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(3-(5,5-difluoro-7,9-dimethyl-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethyl)propanamide 
(85). Following General Procedure 3, 74 was converted to BODIPY®FL conjugate 85.  This was 
purified using preparative RP-HPLC (Method 3) isolating 85 at Rt: 13.82 min which was freeze 
dried to a red/green iridescent solid (0.84 mg, 1.08 μmol, 54%).  LC-MS (ESI+) Rt: 2.80 min (254 
nm, Method 1); (m/z): 777.1 [M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for 
C36H37BClF2N8O3S2, 777.2174; found, 777.2106. [M+Na]
+ calcd. for C36H36BClF2N8NaO3S2, 
799.1994; found, 799.1960. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. for C36H35BClF2N8O3S2, 
775.2029; found, 775.2007. 
N-(2-(3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanamido)ethyl)-6-(3-(5,5-difluoro-7,9-
dimethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)propanamido)hexanamide (86). Following General Procedure 3, 74 was converted to 
BODIPY®FL-X conjugate 86.  This was purified using preparative RP-HPLC (Method 3) isolating 
86 at Rt: 14.37 min which was freeze dried to a red/green iridescent solid (0.54 mg, 0.61 μmol, 
30%). LC-MS (ESI+) Rt: 2.81 min (254 nm, Method 1); (m/z): 890.1 [M(35Cl)+H]+. H.MS-TOF 
(ESI+) (m/z): [M+H]+ calcd. for C42H48BClF2N9O4S2, 890.3015; found, 890.3014. [M+Na]
+ calcd. 
for C42H47BClF2N9NaO4S2, 912.2834; found, 912.2862. H.MS-TOF (ESI-) (m/z): [M-H]
- calcd. 
for C42H46BClF2N9O4S2, 888.2869; found, 888.2853. 
N-(2-(2-(2-(3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-
4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)propanamido)ethoxy)ethoxy)ethyl)-6-(3-
(5,5-difluoro-7,9-dimethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
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yl)propanamido)hexanamide (87). Following General Procedure 3, 76 was converted to 
BODIPY®FL-X conjugate 87. This was purified using preparative RP-HPLC (Method 3) isolating 
87 at Rt: 14.47 min which was freeze dried to a red/green iridescent solid (0.46 mg, 0.47 μmol, 
24%). LC-MS (ESI+) Rt: 2.78 min (254 nm, Method 1); (m/z): 978.3 [M(35Cl)+H]+. H.MS-TOF 
(ESI+) (m/z): [M+Na]+ calcd. for C46H55BClF2N9NaO6S2, 1000.3359; found, 1000.3457. H.MS-
TOF (ESI-) (m/z): [M-H]- calcd. for C46H54BClF2N9O6S2, 976.3394; found, 976.3355. 
6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(3-(5,5-difluoro-7,9-dimethyl-5H-
5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethyl)hexanamide 
(88). Following General Procedure 3, 75 was converted to BODIPY®FL conjugate 88.  This was 
purified using preparative RP-HPLC (Method 3) isolating 88 at Rt: 15.19 min which was freeze 
dried to a red/green iridescent solid (0.71 mg, 0.87 μmol, 43%). LC-MS (ESI+) Rt: 2.82 min (254 
nm, Method 1); (m/z): 819.2 [M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for 
C39H43BClF2N8O3S2, 819.2644; found, 819.2598. [M+Na]
+ calcd. for C39H42BClF2N8NaO3S2, 
841.2463; found, 841.2419. 
6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(2-(2-(3-(5,5-difluoro-7,9-dimethyl-5H-
5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)propanamido)ethoxy)ethoxy)ethyl)hexanamide (89). Following General Procedure 3, 77 
was converted to BODIPY®FL conjugate 89.  This was purified using preparative RP-HPLC 
(Method 3) isolating 89 at Rt:15.97 min which was freeze dried to a red/green iridescent solid 
(0.41 mg, 0.45 μmol, 23%). LC-MS (ESI+) Rt: 2.83 min (254 nm, Method 1); (m/z): 907.2 
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[M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C43H51BClF2N8O5S2, 907.3168; found, 
907.3160. [M+Na]+ calcd. for C43H50BClF2N8NaO5S2, 929.2987; found, 929.2989.  
6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(2-(6-(3-(5,5-difluoro-7,9-dimethyl-5H-
5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)propanamido)hexanamido)ethyl)hexanamide (90). Following General Procedure 3, 75 was 
converted to BODIPY®FL-X conjugate 90.  This was purified using preparative RP-HPLC 
(Method 3) isolating 90 at Rt: 15.59 min which was freeze dried to a red/green iridescent solid 
(0.43 mg, 0.46 μmol, 23%). LC-MS (ESI+) Rt: 2.79 min (254 nm, Method 1); (m/z): 932.3 
[M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C45H54BClF2N9O4S2, 932.3484; found, 
932.3534. [M+Na]+ calcd. for C45H53BClF2N9NaO4S2, 954.3304; found, 954.3387. 
6-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-2-yl)amino)-N-(19-(5,5-difluoro-7,9-dimethyl-5H-
5λ4,6λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)-10,17-dioxo-3,6-dioxa-9,16-
diazanonadecyl)hexanamide (91). Following General Procedure 3, 77 was converted to 
BODIPY®FL-X conjugate 91.  This was purified using preparative RP-HPLC (Method 3) isolating 
91 at Rt: 15.92 min which was freeze dried to a red/green iridescent solid (0.45 mg, 0.44 μmol, 
22%). LC-MS (ESI+) Rt: 2.80 min (254 nm, Method 1); (m/z): 1020.4 [M(35Cl)+H]+. H.MS-TOF 
(ESI+) (m/z): [M+H]+ calcd. for C49H62BClF2N9O6S2, 1020.4009; found, 1020.4011. [M+Na]
+ 
calcd. for C49H61BClF2N9NaO6S22, 1042.3828; found, 1042.3837. 
Ethyl 2-((5-(2-((3-(tert-butoxy)-3-oxopropyl)amino)-7-chloro-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
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yl)methyl)thiazole-4-carboxylate (92). Following General Procedure 1, 57 (547 mg, 1.00 mmol) 
was reacted with β-alanine-tert-butyl ester hydrochloride (727 mg, 4.00 mmol) to afford the title 
compound 92 at 3% MeOH/DCM, a pale yellow solid (585 mg, 0.89 mmol, 89%). LC-MS (ESI+) 
Rt: 2.97 min (254 nm, Method 1); (m/z): 656.0 [M(35Cl)+H]+. The product was reacted following 
General Procedure 2, the intermediate uracil (492 mg, 0.75 mmol) was converted to the title 
compound 92 and isolated at 1.5% MeOH/DCM, a yellow solid (240 mg, 0.36 mmol, 48%). LC-
MS (ESI+) Rt: 3.13 min (254 nm, Method 1); (m/z): 672.0 [M(35Cl)+H]+. 1H NMR (400 MHz, 
DMSO-d6) δ: 12.88 (s, 1H), 8.56 (s, 1H), 7.97 (t, J = 5.5 Hz, 1H), 7.79 (s, 1H), 7.57 (d, J = 8.5 
Hz, 1H), 7.41 (d, J = 2.3 Hz, 1H), 7.36 (dd, J = 8.3, 2.3 Hz, 1H), 6.77 (s, 2H), 5.67 (s, 1H), 5.40 
(d, J = 15.8 Hz, 1H), 5.27 (d, J = 15.8 Hz, 1H), 4.35 (q, J = 6.9 Hz, 2H), 3.42 (app.q, J = 6.2 Hz, 
2H), 2.46 (t, J = 6.4 Hz, 2H), 1.35 (s, 9H), 1.34 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO-
d6) δ: 189.8, 171.1, 169.1, 165.4, 161.0, 148.0, 146.4, 137.5, 133.8, 130.99, 130.97, 130.83, 128.9, 
127.9, 126.8, 122.7, 117.7, 116.8, 110.0, 80.4, 61.4, 49.3, 45.3, 35.2, 28.2, 22.5, 14.4. 
Ethyl 2-((5-(2-((3-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-3-oxopropyl)amino)-7-
chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-
1(2H)-yl)methyl)thiazole-4-carboxylate (93). A stirred solution of 92 (200 mg, 0.30 mmol) in 
DCM (12 mL) was treated with trifluoroacetic acid (6 mL) and stirred at RT for 30 min until 
completion was observed by TLC. The RM was diluted with toluene (25 mL) and concentrated in 
vacuo to 1/5th volume; this was repeated 3 times before concentrating to dryness to afford a yellow 
solid. LC-MS (ESI+) Rt: 2.77 min (254 nm, Method 1); (m/z): 616.2 [M(35Cl)+H]+. The 
intermediate (45 mg, 0.073 mmol) in DCM (3 mL) was treated with Et3N (60 μL) and N-Boc-
ethylenediamine (70 mg, 0.438 mmol) followed by HATU (56 mg, 0.146 mmol) and stirred at rt 
for 24 h. until completion was observed by LC-MS. The RM was quenched with MeOH (1mL) 
 75 
and concentrated directly onto silica. This was purified by FC (1-5% MeOH/DCM) affording the 
tile compound 93 at 5% MeOH/DCM, a yellow solid (35 mg, 0.046 mmol, 63%). LC-MS (ESI+) 
Rt: 2.88 min (254 nm, Method 1); (m/z): 758.2 [M(35Cl)+H]+. 1H NMR (400 MHz, DMSO-d6) δ: 
12.86 (s, 1H), 8.55 (s, 1H), 7.91 (t, J = 5.7 Hz, 1H), 7.88 (t, J = 6.3 Hz, 1H), 7.75 (s, 1H), 7.58 (d, 
J = 8.5 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.36 (dd, J = 8.3, 2.3 Hz, 1H), 6.78-6.75 (m, 1H), 6.75 
(s, 2H), 5.68 (s, 1H), 5.41 (d, J = 15.8 Hz, 1H), 5.26 (d, J = 15.8 Hz, 1H), 4.35 (q, J = 7.0 Hz, 
2H), 3.42 (app.q, J = 6.2 Hz, 2H), 3.04 (app.q, J = 6.0 Hz, 2H), 2.97-2.93 (m, 2H), 2.34 (t, J = 
6.7 Hz, 3H), 1.39-1.36 (m, 9H), 1.34 (t, J = 7.1 Hz, 3H). 
tert-Butyl (2-(3-((4-(1-((4-((1H-tetrazol-5-yl)carbamoyl)thiazol-2-yl)methyl)-2-oxo-4-
thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-7-chloro-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-2-
yl)amino)propanamido)ethyl)carbamate (94). A stirred solution of 93 (30 mg, 0.040 mmol) in 
MeOH (4 mL) was treated with 1M NaOH (120 μL, 0.120 mmol) and heated to reflux for 4 h. 
under N2 until completions was observed by LC-MS. This was cooled, treated with 1M HCl (120 
μL, 0.120 mmol), diluted with toluene (25 mL) and concentrated in vacuo to 1/5th volume; this 
was repeated 3 times before concentrating to dryness to afford a yellow solid. This was dissolved 
in DMF (2 mL) treated with DIPEA (35 μL) and 5-aminotetrazole monohydrate (25 mg, 0.240 
mmol) followed by PyBroP® (28 mg, 0.60 mmol) and stirred at rt for 4 h. until completion was 
observed by LC-MS. The RM was quenched with water (ca. 2 drops) and concentrated in vacuo 
azeotroping DMF with toluene (3 x 50 mL) to afford an orange oil. This was purified by FC 
washing with 10% MeOH/DCM before eluting off the desired compound with 10% MeOH/DCM 
w. 1% acetic acid affording the title compound 94 (9 mg, 0.011 mmol, 28%). LC-MS (ESI+) Rt: 
2.68 min (254 nm, Method 1); (m/z): 797.4 [M(35Cl)+H]+. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. 
for C32H32ClN12O5S3, 795.1475; found, 795.1437. 
1H NMR (500 MHz, DMSO-d6) δ: 12.92-12.78 
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(br.s, 1H), 8.53-8.43 (br.s, 1H), 7.99-7.89 (s, 2H), 7.74-7.68 (br.s, 1H), 7.58 (d, J = 8.4 Hz, 1H), 
7.40 (d, J = 2.2 Hz, 1H), 7.35 (dd, J = 8.4, 2.2 Hz, 1H), 6.78-6.76 (m, 2H), 5.68 (s, 1H), 5.40 (d, 
J = 15.9 Hz, 1H), 5.29 (d, J = 15.9 Hz, 1H), 4.12-4.09 (m, 2H), 3.41 (app.q, J = 6.5 Hz, 2H), 3.06-
3.03 (m, 2H), 2.99-2.94 (m, 2H), 1.36-1.21 (m, 9H). 
(E)-2-((5-(7-Chloro-2-((3-((2-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)acetamido)ethyl)amino)-3-
oxopropyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-carboxamide (95). 
Following General Procedure 3, 94 was converted to BODIPY®630/650 conjugate 95.  This was 
purified using preparative RP-HPLC (Method 4) isolating 95 at Rt: 10.80 min which was freeze 
dried to a blue iridescent solid (0.35 mg, 0.31 μmol, 16%).  LC-MS (ESI+) Rt: 3.00 min (254 nm, 
Method 1); (m/z): 1129.5 [M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for 
C50H41BClF2N14O5S4, 1129.2011; found, 1129.2000. [M+Na]
+ calcd. for C50H40BClF2N14NaO5S4, 
1151.1831; found, 1151.1823. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. for C50H39BClF2N14O5S4, 
1127.1866; found, 1127.1818. 
(E)-2-((5-(7-Chloro-2-((3-((2-(3-(5,5-difluoro-7,9-dimethyl-5H-5λ4,6λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethyl)amino)-3-oxopropyl)amino)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-carboxamide (96). Following General Procedure 3, 
94 was converted to BODIPY®FL conjugate 96.  This was purified using preparative RP-HPLC 
(Method 3) isolating 96 at Rt: 12.05 min which was freeze dried to a red/green iridescent solid 
(0.21 mg, 0.22 μmol, 11%). LC-MS (ESI+) Rt: 2.76 min (254 nm, Method 1); (m/z): 971.4 
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[M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C41H39BClF2N14O4S3, 971.2185; 
found, 971.2189. [M+Na]+ calcd. for C41H38BClF2N14NaO4S3, 993.2004; found, 993.2002. 
(E)-2-((5-(7-Chloro-2-((3-((2-(6-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-
yl)vinyl)phenoxy)acetamido)hexanamido)ethyl)amino)-3-oxopropyl)amino)-4H-
benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-carboxamide (97). Following General Procedure 3, 
94 was converted to BODIPY®630/650-X conjugate 97.  This was purified using preparative RP-
HPLC (Method 4) isolating 97 at Rt: 11.28 min which was freeze dried to a blue iridescent solid 
(0.44 mg, 0.35 μmol, 18%). LC-MS (ESI+) Rt: 2.99 min (254 nm, Method 1); (m/z): 1242.4 
[M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for C56H52BClF2N15O6S4, 1242.2852; 
found, 1242.2858. [M+Na]+ calcd. for C50H40BClF2N14NaO5S4, 1264.2671; found, 1264.2624.  
(E)-2-((5-(7-Chloro-2-((3-((2-(6-(3-(5,5-difluoro-7,9-dimethyl-5H-5λ4,6λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)hexanamido)ethyl)amino)-3-
oxopropyl)amino)-4H-benzo[5,6]cyclohepta[1,2-d]thiazol-4-yl)-2-oxo-4-thioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-N-(1H-tetrazol-5-yl)thiazole-4-carboxamide (98). 
Following General Procedure 3, 94 was converted to BODIPY®FL-X conjugate 98.  This was 
purified using preparative RP-HPLC (Method 4) isolating 94 at Rt: 12.69 min which was freeze 
dried to a red/green iridescent solid (0.35 mg, 0.31 μmol, 18%). LC-MS (ESI+) Rt: 2.75 min (254 
nm, Method 1); (m/z): 1084.6 [M(35Cl)+H]+. H.MS-TOF (ESI+) (m/z): [M+H]+ calcd. for 
C47H50BClF2N15O5S3, 1084.3026; found, 1085.3014. [M+Na]
+ calcd. for C47H49BClF2N15O5S3, 
1106.2845; found, 1128.2825. H.MS-TOF (ESI-) (m/z): [M-H]- calcd. for C47H48BClF2N15O5S3, 
1082.2880; found, 1082.2839. 
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General Pharmacology Methods: 
cDNA constructs 
To create Nluc-P2Y2R constructs, human P2Y2R DNA  (obtained from the Missouri S&T cDNA 
Resource Centre, Bloomsberg, PA), was amplified by PCR to remove the methionine start signal 
and cloned into pCR®2.1 (linearized vector; Invitrogen). The P2Y2R was then sub-cloned in-frame 
with the membrane signal sequence of the 5HT3A receptor and the full length sequence of Nluc 
luciferase. The NanoLuc-tagged receptors expressed in 1321N1 cells exhibited normal calcium 
signals (EC50 for UTPS of 91 ± 12 nM; n=3). 
Cell culture and cell line generation  
1321N1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 
10% fetal calf serum (FCS H.I.) and 2 mM L-glutamine at 37°C, 5% CO2. Mixed-population Nluc-
P2Y2R-1321N1 cell lines were generated by transfecting Nluc–P2Y2R construct using 
Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions and then 
subjecting the cells to selective pressure (1 mg/mL G418) for 2–3 weeks. The mixed cell 
population was then dilution-cloned to obtain cell lines originating from a single cell. Screening 
for active clones was initially performed using the calcium mobilization assay, followed by 
detection of luminescence on addition of the Nluc substrate furimazine. On this basis, a single 
active cloned cell line was selected for use in all NanoBRET assays. 1321N1 cells expressing wild-
type P2Y2R (P2Y2R-1321N1) were gifted by Dr Elizabeth Rosethorne, University of Nottingham.   
Calcium mobilization assay  
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P2Y2-1321N1 cells seeded into black-sided 96-well view plates were incubated at 37°C (no 
CO2) for 45 min in a total volume of 100 μl of HEPES buffered saline solution (HBSS; 10 mM 
HEPES, 10 mM glucose, 145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM sodium pyruvate, and 
1.3 mM CaCl2) containing 2.5 mM probenecid, 2.3 μM Fluo 4AM, 0.023% pluronic acid, 0.5mM 
Brilliant Black, 1U/ml apyrase and the ligand under investigation or vehicle. Plates were then 
loaded onto a plate reader (FLEXstation; Molecular Devices, Sunnyvale, CA) and fluorescence 
measured (excitation, 485 nm; emission, 525 nm) every 1.52 s for up to 200 s with the addition of 
UTPS at 15 s. For investigation of BODIPY®FL-labelled ligands, the Fluo 4AM was replaced 
with 2.0 μM X-Rhod-1 AM (excitation, 584 nm; emission, 612 nm). 
NanoBRET assay 
 Saturation and competition binding assays were performed according to the methodology of 
Stoddart.18 Briefly, assays were performed on stably transfected NlucP2Y2-1321N1 cells that were 
seeded 24 h prior to experimentation in white Thermo Scientific Matrix 96-well microplates. 
Medium from each well was removed and replaced with HBSS containing apyrase (1U/mL) and 
the required concentration of fluorescent ligand with or without competing ligand. Upon the 
addition of fluorescent ligand, cells were incubated for 1 h at 37°C (no CO2). Nluc substrate 
furimazine (Promega) was then added to a final concentration of 10 μM and the plate incubated 
for a further 5 min 37°C (no CO2). Luminescence and resulting BRET were measured using the 
PHERAstar FS plate reader (BMG Labtech) at room temperature. Sequential measurements of 
filtered light emissions were made at 460 nm (80-nm bandpass) and >610 nm (longpass) and the 
raw BRET ratio calculated by dividing the >610-nm emission by the 460-nm emission (97). For 
assays involving 98, measurements were made at 475 nm (30-nm bandpass) and 535 nm (30-nm 
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bandpass) and the raw BRET ratio calculated by dividing the 535-nm emission by the 475-nm 
emission. 
Confocal microscopy 
P2Y2R-1321N1 cells were grown to approximately 80% confluency on 8-well Labtek 
chambered cover glasses (Nunc Nalgene) in normal growth medium. Growth medium was 
removed and replaced with HBSS containing apyrase (1U/ml) and either 1 (10µM) or vehicle and 
the cells incubated for 30 min at 37°C (no CO2). Cells were then incubated with 97 or 98 at the 
required concentration for 10 min at room temperature, prior to collection of single equatorial 
confocal images. Images were obtained on a Zeiss LSM710 confocal microscope using a 40× c-
Apochromat 1.2NA water-immersion objective. For 97, images were collected using 633 nm 
excitation, a 488/561/633 dichroic and emission collected through a 650LP filter. For 98, 488 nm 
excitation was used with the same dichroic, with emission collected using a LP575 filter. In each 
case, a pinhole diameter of 1 Airy Unit was used, and laser power, gain and offset were kept the 
same for samples within each experiment. In both cases, images are presented as representative of 
an individual experiment with matched conditions. Linear adjustments to image brightness and 
contrast have been applied equally across all comparative images using Zen software to prepare 
images for presentation. 
Data analysis 
All data were analyzed using GraphPad Prism 6. 
For the calcium mobilization experiments as none of the compounds synthesized as part of this 
study showed any partial agonist action, estimated affinity values (pKB) were calculated from the 
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shift of the agonist concentration response curves in the presence of the fluorescent antagonists 
using equation 1: 
𝐷𝑅 = 1 +  
[𝐵]
𝐾𝐵
 
(1) 
Where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical 
response in the presence and absence of antagonist, [B]. pKB is –log KB. 
 
Total and non-specific saturation binding curves were fitted simultaneously using equation 2: 
𝐵𝑅𝐸𝑇 𝑅𝑎𝑡𝑖𝑜 =  
𝐵𝑚𝑎𝑥 × [𝐵]
[𝐵] +  𝐾𝑑
+  ((𝑀 × [𝐵]) + 𝐶) 
(2) 
where Bmax is the maximal specific BRET signal, [B] is the concentration of fluorescent ligand in 
nM, Kd is the equilibrium dissociation constant in nM, M is the slope of the non-specific binding 
component and C is the intercept with the Y-axis. pKd is – logKd. 
The competition binding curves were fitted using equation 3: 
𝑲𝒊 =  
𝑰𝑪𝟓𝟎
𝟏 +  
[𝑳]
𝑲𝒅
 
(3) 
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where [L] is the concentration of  98 in nM and Kd is the equilibrium dissociation constant of 98 
in nM.  The IC50 is calculated as in equation 4: 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 =  
100 × [𝐴]
[𝐴] +  𝐼𝐶50
 
(4) 
where [A] is the concentration of unlabelled competing drug and IC50 is the molar concentration 
of this competing ligand required to inhibit 50% of the specific binding of the concentration [L] 
of the labelled ligand.  
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